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Investigating the effect of liposomal membrane fluidity and antibody mobility on 
endothelial cell targeting 
 
Abstract 
           Atherosclerosis is initiated by the adhesion of leukocytes to the endothelial 
surface of arteries followed by migration beneath the intima.  Current therapies to 
combat atherosclerotic plaque, such as statins or antihypertensive drugs, treat 
atherosclerosis indirectly; they do not specifically target inflamed vasculature or improve 
the vascular condition.  Few studies have focused on antibody mobility or membrane 
fluidity as an approach to improve drug delivery vehicle binding and uptake.   
           Here, we present a biomimetic liposomal design targeting vascular adhesion 
molecule (VCAM1) and E-selectin, which are upregulated on inflamed endothelial cells 
(ECs).   We hypothesized that increased lateral antibody diffusivity may be used as a 
strategy to enhance liposome targeting to ECs expressing high levels of VCAM1 and E-
selectin.  We first characterized the physical properties of our liposomal system, 
including membrane fluidity and quantification of antibody surface density, and 
evaluated the temporal EC expression of VCAM1 and E-selectin.  We then examined 
the effects of membrane fluidity, antibody surface density, and incubation time on 
activated EC binding and uptake.   Finally, we also conducted a preliminary in vivo 
study where we assessed the biodistribution of our liposomes.    
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           The results of this dissertation may be utilized to design liposomes with 
enhanced targeting efficiency to inflamed endothelium, present not only in 
atherosclerosis but also in a wide range of vascular inflammatory conditions.  These 
liposomes can be further developed to have diagnostic, imaging and/or therapeutic 
capabilities. 
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Chapter 1.  
Introduction 
1.1 Cardiovascular Disease: Current Treatments and Diagnostic Tools 
  Cardiovascular disease is, according to statistics, considered to be a pandemic 
affecting millions of people in developed countries.  According the World Health 
Organization, 18 million people die annually from cardiovascular disease (CVD) and by 
the year 2030, this number is projected to increase to 24 million deaths per year [1].  
Cardiovascular disease includes complications such as heart attack and ischemic 
stroke, but also encompasses heart failure, arrhythmia, and heart valve problems.   
Atherosclerosis is known to be the major contributor of coronary heart disease, carotid 
artery disease, peripheral arterial disease, and chronic kidney disease.  It is a condition 
that develops when narrowing of the arteries occurs due to the presence of plaque. 
  Current life-long treatments of atherosclerosis include the administration of 
medications such as: β blockers, angiotensin-converting-enzyme (ACE) inhibitors and 
calcium blockers to treat hypertension, aspirin to inhibit production of thromboxane, 
statins to decrease cholesterol levels, and anti-ischemic nitrates [2,3].  Preventive life 
style changes such as maintaining a healthy diet, abstaining from smoking, maintaining 
a healthy weight, exercising, and being physically active are also recommended [4].  
When patients are in the late stages of the disease, invasive surgical procedures are 
required and include angioplasty and coronary artery bypass grafting [5].   
  There are several limitations in how we currently diagnose coronary heart and 
carotid artery disease caused by atherosclerosis.  Narrowing of the arteries is  
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diagnosed by detecting any artery blood flow insufficiencies via an electrocardiogram 
that may be accompanied with a treadmill exercise test and/or with a coronary 
angiography [5].  Efforts have been placed on developing non-invasive cardiac imaging 
techniques that include functional imaging, focused on detecting hemodynamic 
changes, and anatomical imaging, focused on visualizing the coronary artery tree [6].  
These techniques although powerful in certain aspects, tend to lack in others [7–9].  For 
example, techniques like positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) have high sensitivity, but lack good spatial 
resolution.  Similarly, magnetic resonance imaging (MRI) and computed tomography 
(CT) have great spatial resolution, but less sensitivity.  Recent focus has gone into 
investigating cardiac molecular imaging involving the targeting of pathophysiologic 
molecules of interest, such as vascular cell adhesion molecule1 (VCAM1), to achieve 
imaging with greater specificity and resolution [7,9,10].   
There are also limitations to the current treatment modality of atherosclerosis.  
Current medications do not address changes in vessel wall mechanics or directly treat 
plaque formation. Targeted therapeutics that promote vasodilation, inhibit proteases (to 
prevent thrombosis), and reestablish vessel compliance may revolutionize clinical 
treatment by improving the physical condition of the vessel wall. The inability to 
accurately target inflamed areas of the endothelium has hindered the design of local 
cardiovascular therapies. Improved targeting techniques are necessary to develop 
radically new treatments for cardiovascular disease.  
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1.2 The Role of Inflammation in Atherosclerosis 
The role of inflammation in atherosclerosis has been elucidated during the last 
two decades.  There are three main stages of atherosclerosis; inflammation is present 
at every single stage.  A variety of conditions such as low-density lipoprotein (LDL) 
oxidation, hypertension, diabetes, obesity, and infection are thought to trigger the initial 
stages of atherosclerosis [11].  During the early stages of atherosclerosis, patches of 
endothelium begin to express molecules termed cell adhesion molecules (CAMs) that 
bind specifically to circulating leukocytes [12].  These CAMs include, VCAM1, 
intercellular cell adhesion molecule1 (ICAM1), and selectins (P-, E-, and L-), which all 
have different functions in the inflammatory cascade.  Selectins are type-I 
transmembrane glycoproteins that bind to sialylated carbohydrate moieties present on 
target proteins.  E-selectin or CD62A has a molecular weight ranging between 107 kDa 
– 115 kDa and is responsible for mediating the rolling of leukocytes on the surface of 
endothelial cells (ECs) [12].  Both VCAM1 and ICAM1 are members of the 
immunoglobulin superfamily and mediate the firm adhesion of leukocytes on ECs after 
the initial rolling stage mediated by the selectins [13].   VCAM1-expressing ECs bind to 
the leukocytes via very late antigen4 (VLA4), an α4β1 integrin [13,14].  The third stage of 
atherosclerosis involves the chemotactic migration of leukocytes into the intima.  Once 
inside the vascular wall, leukocytes secrete cytokines that promote the migration and 
proliferation of smooth muscle cells (SMCs).  These SMCs express matrix 
metalloproteinases (MMPs), which in turn degrade collagen and elastin allowing SMCs 
to penetrate into the elastic laminae.  Ultimately, foam cells express collagenases that 
weaken the fibrous cap and consequently, make it vulnerable to rupture.  T lymphocytes  
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and macrophages increase the expression of pro-coagulant tissue factor, which is 
responsible for triggering a thrombus when plaque rupture occurs, leading to acute 
complications such as stroke. 
 
1.3 Liposomes as Drug Delivery Vehicles 
Liposomes are defined as phospholipids that self-assemble into vesicles when 
exposed to an aqueous phase [15].  Since their discovery in the 1960s by A. D. 
Bangham, liposomes have become one of the most comprehensively studied drug 
delivery vehicles.  Additionally, liposomes have been utilized for other related 
applications including vaccines, gene therapy and imaging [16–18].  There exists great 
versatility to the design of liposomes because of the availability of lipids with different 
physical characteristics such as pH-sensitivity, light-sensitivity, charge, fluorescence 
and polymerizability.  Liposomes are also able to encapsulate both hydrophilic and 
hydrophobic substances within the aqueous compartment and within the lipid bilayer, 
respectively.  
  When lipids self-assemble in water they tend to form lamellar bilayers.   
Liposomes can be classified into two categories: multilamellar vesicles (MLVs) 
containing more than one concentric lamellar bilayer and unilamellar vesicles containing 
only one bilayer.  MLVs can range between 0.1 to 10 µm while the range of sizes of 
unilamellar vesicles varies.  Small unilamellar vesicles (SUVs) are less than 100 nm, 
large unilamellar vesicles (LUVs) are between 100 to 500 nm and giant unilamellar 
vesicles (GUVs) are greater than 1 µm in size [17].  SUVs are most commonly used for  
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drug delivery applications due to their size and homogeneity.  The lamellarity and size 
distribution of MLVs is usually too heterogeneous, which renders them inadequate as 
drug carriers.  Below are some detailed examples of different clinical applications 
targeting various diseases in which liposomes have been used as drug delivery 
vehicles.   
1.3.1 Liposomes and the Blood Brain Barrier 
Transporting therapeutic molecules across the blood brain barrier (BBB) for 
central nervous system (CNS) access has long been a challenge since more than 98% 
of neuronal drug molecules cannot cross the BBB [19].  Passive crossing of drugs 
through the BBB is possible with the correct lipophilicity and a molecular weight below 
500 Da [20].  Because of these limitations, pathways involving liposomes have been 
explored for efficient delivery of therapeutics to the brain.  Three mechanisms of BBB 
transport include carrier-mediated transport (CMT), active-efflux transport (AET), and 
receptor-mediated transcytosis (RMT) [19].   CMT involves the transport of small-
molecule hydrophilic nutrients through transporter proteins into and out of the brain, and 
AET allows transport of low molecular weight lipophilic metabolic products from the 
brain to the blood. RMT uses peptide-specific receptors to mediate the transport of 
essential circulating proteins and peptides, such as insulin, leptin, and transferrin, into 
the brain. Understanding these mechanisms allows for the design of drug delivery 
vehicles that can target the brain while bypassing the rejection from the BBB.   
Liposomes between 80-100 nm have been used to target the CNS due to their 
lipophilic character [21].  To avoid immediate clearance when introduced systemically,  
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polyethylene glycol (PEG) can be inserted into the lipid bilayer for avoidance of protein 
adsorption and recognition by macrophages. Many RMT pathways have been used to 
deliver liposomes across the BBB. The transferrin receptor (TR) provides iron to cells. 
Although designing vehicles that bind to transferrin itself cannot be used for specific 
BBB targeting due to high plasma levels, conjugation of specific monoclonal antibodies 
(mAb) against TR has been explored for the fabrication of drug delivery vehicles. Using 
another RMT approach, specific mAbs targeting the human insulin receptor (HIR) have 
also been used. The conjugation of mAbs to liposomes creates what is termed 
immunoliposomes.  
Researchers have designed “Trojan Horse Liposomes” (THL) for BBB delivery of 
therapeutics with in vivo stability, which allow for the stealth passage of the liposomes 
through the BBB and then the release of its therapeutic contents [22].  For example, 100 
nm 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC):didodecyldimethylammonium 
bromide (DDAB):Distearoylphosphatidylethanolamine  (DSPE)-PEG 2000 liposomes 
have been made to encapsulate single DNA strands encoding for luciferase or β-
galactosidase [23].  This liposome formulation is neutral in charge, which allows for in 
vivo stability in blood. DSPE-PEG 2000 allows the evasion of clearance by the immune 
system.  Additionally, 1-2% of the PEG strands were conjugated with the OX26 mAb rat 
TR. After intravenous injection of these immunoliposomes in rats, it was found that 
specific gene expression in the brain was achieved. Targeting the HIR has also been 
explored using the same liposome composition at 85 nm [24].  The immunoliposome 
was selectively targeted to the murine 83-14 mAb against the HIR in the rhesus monkey 
brain in vivo.  Global expression of β-galactosidase was shown in the rhesus monkey  
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brain, which shows the feasibility of using immunoliposomes for gene therapy in the 
brain.  Although these mAbs cannot be used in humans, genetically engineered 
humanized mAbs to HIR have been developed and may be used in humans in the 
future [25]. 
Liposomes have also been used to combat specific neurodegenerative diseases. 
Research has shown that immunoliposomes encapsulating tyrosine hydroxylase with 
TR targeting functionality using OX26 mAbs against experimental Parkinson’s disease 
models can improve rat motor function [26].  RNAi therapies have also been 
investigated for anti-angiogenic brain tumor therapies targeting human epidermal 
growth factor receptor (EGFR) [27].  Immunoliposomes encapsulated short hairpin RNA 
(shRNA) against EGFR, and passage across the BBB was achieved using both the 
murine 83-15 mAb to HIR and the rat 8D3 mAb to the mouse TR. Intravenous 
administration of immunoliposomes successfully suppressed EGFR expression and 
increased survival of mice with advanced intracranial brain tumors. 
Although using liposomes to bypass the BBB has not proceeded to human 
clinical trials, there is much promise in using these materials for treating 
neurodegenerative diseases and brain tumors in the future. 
1.3.2 Liposomes and Cancer  
The delivery of low molecular weight chemotherapeutics to tumors is limited by 
high and rapid uptake by macrophages in the reticuloendothelial system (RES) of the 
kidneys and liver and inactivation of active drugs due to protein binding [28].  However, 
tumors exhibit high microvessel permeability to higher molecular weight compounds due  
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to a discontinuous basement membrane, fenestrated endothelium, and increased 
transendothelial transport compared to normal tissues [29].  Tumors possess these 
pathophysiological characteristics to sustain adequate levels of oxygen and nutrients for 
growth, and this phenomenon has been termed the “enhanced permeability and 
retention effect” (EPR).  Similarly, long-circulating liposomes that are modified with PEG 
have been shown to increase deposition within extravascular and extracellular tumor 
areas due to “leaky” vasculature and an irregular lymphatic system [30,31].   Although 
using macromolecules or liposomes has increased tumor targeting, many limitations 
exist, including small avascular tumors that cannot be targeted, high interstitial fluid 
pressure preventing diffusion into the tumor parenchyma, and increased toxicity due to 
high drug retention [28].   
Cationic 100-200 nm liposomes have been designed to target the tumor 
vasculature specifically with the aim of depleting oxygen and nutrient supply from the 
tumors [32].  PEGylated, cationic 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC): 
1,2-diacyl-3-trimethylammonium  propane (DOTAP):cholesterol:PEG- 
distearoylphosphatidylethanolamine (PEG-PE) liposomes were shown to preferentially 
accumulate in the tumor vasculature compared to normal vessels 24 hr after tail vein 
injection in tumor bearing mice [31].   It was found that cationic character in the 
liposomes improved specific targeting to tumor vessels and including PEG allowed for 
long-circulation of liposomes in the bloodstream without interfering with tumor 
vasculature uptake. Many preclinical trials in murine models of human cancer have 
been performed using cationic liposomes to show that delivering chemotherapeutics to 
tumor vasculature can suppress tumor growth [32].  For example, a cationic formulation  
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of doxorubicin encapsulating egg phosphatidylcholine (EPC):Chol:dimethyl dioctadecyl 
ammonium bromide (DDAB) (40:40:20) and PEG- PE was shown to increase mouse 
survival after tail vein injection at 5 mg/kg [33].  In addition, cationic cisplatin loaded 
hydrogenated soybean phosphatidylcholine (HSPC):Chol:3,5-dipentadecycloxybenzamidine 
hydrochloride (TRX-20) (50:42:8) and PEG-PE liposomes were administered through 
intracardiac injection at 3.5 mg/k [34].  It was found that these liposomes accumulated in 
the tumor and suppressed tumor growth and liver metastasis while significantly 
increasing the survival of the mice.  
The success of preclinical trials using cationic liposomes for cancer treatment has 
led to clinical trials in humans.  The cationic composition of DOTAP:DOPC:paclitaxel  or 
fluorouracil (5-FU) (50:47:3), named EndoTAG-1, has been used in phase I, phase Ib, 
and phase II clinical trials [32,35].  In phase I trials, EndoTAG-1 using 5-FU was 
tolerated and safe in patients with advanced, metastatic gastrointestinal cancer. 
Patients with metastatic breast cancer were treated in phase II trials with EndoTAG-1 
using paclitaxel, and it was found that after a dose of 0.55 mg/kg, 6% of patients had a 
partial response while 28% presented with stable disease.  Nausea and vomiting related 
to the infusion were the main side effects.  Ongoing phase II trials in patients with 
advanced pancreatic cancer are being conducted with EndoTAG-1 using paclitaxel in 
combination with gemcitabine.  It has been shown that 75% of patients survived after 1 
year, demonstrating the effectiveness of using this liposome formation for treatment of 
advanced pancreatic cancer [35]. 
Other methods of targeting tumors include conjugation of tumor-specific mAbs 
and peptides. Immunoliposomes made from soy phosphatidyl choline (PC):Chol:cyanur- 
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PEG2000-PE:3,3′-dioctadecyloxacarbocyanine perchlorate (DiO) in a ratio of 
64.5:30:5:0.5 mol% were conjugated with anti- vascular cell adhesion molecule (a-
VCAM) monoclonal antibody since VCAM1 is overexpressed on tumor vessels [36].   
After intravenous injection of the liposomes in mice with human Colo677 non-small cell 
lung tumor xenografts, it was found that the immunoliposomes selectively targeted the 
tumor vascular endothelial cells.  Some concerns still remain regarding the specificity of 
these immunoliposomes due to the presence of VCAM1 expression by healthy 
endothelial cells.  For increased specificity, the commercially available Doxil (PEGylated 
liposomal doxorubicin) was modified with PEG3400-DSPE conjugated to the 2C5 mAb to 
bind to cancer cells but not normal cells [37].  This liposome formulation was able to 
increase the efficacy of doxorubicin by suppressing the growth of breast, colon, and 
prostate cancer tumors in mice. 
Another study used in vivo phage display to probe specific antibodies that target 
tumor vessels for anti-angiogenic purposes [38].  Doxorubicin-loaded PEGylated DSPE 
liposomes conjugated with specific tumor endothelial cell targeting peptides PIVO-8 and 
PIVO-24 were shown to enhance the efficacy of the chemotherapeutic in lung, breast, 
liver, pancreatic, and colon cancer xenografts by significantly decreasing vessel density 
in solid tumors, increasing cancer cell death, and inhibiting tumor growth.  Targeting 
tumor angiogenesis is not sufficient to remove a tumor completely.  Tumors are able to 
receive nutrients and oxygen from surrounding tissue.  To combat this, multifunctional 
liposomes have been fabricated that target not only the tumor vasculature but also the 
surrounding tumor cells [39].  Doxorubicin loaded immunoliposomes were made from 
HSPC:CHOL:DSPE-PEG2000:DSPE-PEG2000-maleimide and conjugated to the NGR  
 
11 
 
peptide that targets an angiogenic endothelial cell marker to bind and kill angiogenic 
blood vessels.  The immunoliposomes were also modified with anti-GD2 mAbs, an 
antibody to a disialoganglioside receptor expressed in neuronal cancer cells, for 
targeting the tumor periphery independent of the vasculature. The two liposomal 
formulations were administered sequentially, and a synergistic effect was observed 
where tumor proliferation was inhibited and endothelial cell density decreased 
significantly in neuroblastoma animal models. 
Liposomes have been shown selectively target tumor vasculature using the EPR 
and also specific targeting ligands. Although many limitations still exist, including the 
inability to remove the entire tumor, liposome formulations have been shown to reduce 
tumor size and increase survival in animal models. Cationic lipids are currently being 
tested in human clinical trials for multiple advanced cancers. Using liposomes for 
targeting tumors is promising and a number of targeted treatments may successfully 
translate into the clinic in the near future. 
1.3.3 Liposomes and the Immune System 
  Immunosuppression and immunostimulation via nanoparticle systems, 
particularly liposomes, has been widely investigated.  Liposomes have been engineered 
to target and interact with immune cells but have also been designed to avoid immune 
detection.  Activation of the immune system is highly desirable when developing 
vaccines or enhancing immune responses to diseases such as cancer.   
Immunosuppression, on the other hand, is necessary to a certain degree when 
introducing a drug delivery vehicle in the body.  Systemically-administered drug carriers  
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tend to be rapidly cleared from the bloodstream by the immune system.  Drug carriers 
must therefore elude detection in order to prolong their circulation time and increase 
their binding efficiency.  Autoimmune disorders, characterized by a marked increase in 
an immune response against healthy cells, can also evidently benefit from a modulated 
immune inhibitory effect induced by drug carriers.   
  Liposomes are ideal immunoadjuvants because of their safety, ability to 
encapsulate a wide variety of molecules and most importantly because of their high 
accumulation in the RES organs [40].  They may have covalently attached antigens on 
their surface or may encapsulate antigens in order to elicit an immune response.   
Liposome-based vaccines against HIV, hepatitis, tuberculosis, influenza and malaria 
have been investigated [41–45].  For example, Schwendener et al. reported methods of 
liposomal vaccine preparations based on encapsulation of antigenic peptides derived 
from the hepatitis C virus and plasmid DNAs encoding glycoproteins of the lymphocytic 
choriomeningitis virus [46].  Vaxfectin, a cationic lipid-based adjuvant for influenza 
vaccines was shown to elicit the strongest antibody response in vivo when compared to 
the commercially available seasonal trivalent influenza vaccine [42].  Steers et al. 
formulated a liposome-based HIV vaccine composed of lipid A and encapsulating the 
antigen Gag p24, which is often used in HIV-1 vaccine candidates.   Results 
demonstrated that liposomal carrier induced activation of CD4+ and CD8+ T-cells in the 
spleen and lymph nodes of mice [47].  Liposomes have also been proposed as a means 
to enhance cell-mediated immunity in general, i.e. without targeting a specific disease.  
For example, Inoue et al. reported an induced natural killer T (NKT) cell response in 
vivo by liposomes composed of DOTAP:DOPE, cholesterol and a glycosphingolipid  
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[48].  Liposomal vaccine administration routes other than systemic delivery have also 
been pursued.  Nasal and transcutaneous vaccinations have been reported [47,49].   
Liposomes for nasal immunization formulated with mannotriose (Man3),   
dipalmitoylphosphatidylethanolamine (DPPE), and coated with a neoglycolipid showed 
an increase in uptake by antigen presenting cells (APCs) when compared to non-coated 
control liposomes [50].  
Inflammation is a natural immune response and represents one of the key 
characteristics of autoimmune diseases, organ transplant rejections, and inflammatory 
disorders such as asthma.  Most liposome studies have therefore focused on combating 
inflammation by encapsulating anti-inflammatory drugs or immune inhibitors.  Recently, 
a study done by Capini et al. showed that egg phosphatidylcholine liposomes, which 
encapsulated a lipophilic innate immune inhibitor (NF-κB) and ovalbumin, induced 
antigen-specific tolerance in a rheumatoid arthritis mouse model [51].    
Immunosuppression is crucial for successful organ transplantations.  Liposomal 
nanocarriers have been used to target immune cells as a way to decrease the incidence 
of graft-versus-host disease.  In 2009, a clinical trial involving patients receiving a 
liposome-based immunosuppressant after a lung transplant was reported.  Typical 
immunosuppressant drug therapy is systemically administered and has not proved to be 
effective; the leading cause of death after lung transplantation is immune rejection.   
Aerosolized SUVs 40 to 50 nm in diameter encapsulating cyclosporine A (CsA), an 
interleukin-2 inhibitor blocking T-lymphocyte proliferation, were administrated to patients 
via electronic nebulizers.  Results showed that intrapulmonary deposition of the 
liposomal drug carrier was therapeutically relevant and well tolerated by the patients  
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[52].  However, further long-term clinical trials must assess the efficacy of the liposomal 
drug solution in terms of reducing the mortality rate caused by immune rejection in 
patients with lung transplants.  Cationic liposome-DNA complexes have also been 
investigated as a possible vaccine against asthma [53].  A vaccine composed of Ag 
proteins and liposome-DNA complexes was administered to allergen-sensitized mice 
and results showed the vaccine could induce production of allergen-specific T cells and 
diminish the development of airway hyper-responsiveness, a hallmark of asthma.  
 
1.4 The Endothelium as a Drug Delivery Target 
Endothelial cells were once thought of as a quiescent cell population having no 
specific function other than being a nonreactive barrier to protect tissues [54].     
However, the endothelium is at the interface between the bloodstream and tissues, thus 
giving it the important function of regulating the transport of molecules and cells into 
tissues.  In the late 1980s and early 1990s it was established that the endothelium 
responded to various cytokines including interleukin-1α and β (IL-1α and β), tumor 
necrosis factor (TNF), lymphotoxin (LT), interferon-γ (IFN-γ) and transforming growth 
factor-β (TGF- β), during processes such as immune responses, angiogenesis and 
activation [42,55,56].  It was shown that exposure of endothelial cells to these cytokines 
(IL-1 and TNF) increased the expression of cell adhesion molecules, such as ICAM1, 
ICAM2, and VCAM1 and members of the selectin family including E-selectin, L-selectin, 
and P-selectin [42,54,56,57].  Studies also showed that the levels of these cellular 
adhesion molecules and selectins were elevated 2-, 3-, and up to 23-fold in numerous  
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diseased conditions such as inflammation, atherosclerosis, hypertension, diabetes, 
septic shock, tumor metastasis, arthritis, gastrointestinal inflammation, asthma, adult 
respiratory distress syndrome, ischemia and reperfusion injury, vasculitis, hepatic 
diseases, renal diseases, central nervous system diseases and transplant rejections 
[58–61].  
Drug delivery systems targeting the endothelium have taken advantage of the 
increased surface expression of CAMs and selectins on diseased endothelial cells.   
Liposomes, in particular, represent one of the most studied drug delivery systems 
targeting the endothelium due to their stability under physiological conditions, 
biocompatibility, ease of fabrication, homogeneity, narrow size distribution, and ability to 
encapsulate both hydrophilic and hydrophobic drugs [62].  Liposomes decorated on the 
surface with antibodies aE-selectin, aICAM1, aVCAM1 or a combination of these has 
been studied [31,36,63–66].  For example, Gosk et al. reported successful selective in 
vitro and in vivo targeting of tumor blood vessels by aVCAM1-conjugated liposomes 
[36].   
One of the major challenges to deliver drugs to the endothelium is the rapid 
clearance of the drug carrier from the bloodstream by the reticuloendothelial system 
(RES) in addition to rapid renal clearance and hepatic uptake.  This problem has been 
addressed by sterically stabilizing the liposomes through the use of PEG, as previously 
mentioned, which provides a barrier against antibody opsonization.  Spragg et al. 
prepared pH-sensitive, cationic and classical liposomes in addition to sterically 
stabilized liposomes conjugated with aE-selectin.  After activation with IL-1β, human 
vein endothelial cells (HUVECs) showed increased binding of classical and sterically  
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stabilized liposomes [63].  Although PEG has been extensively studied and has been 
shown to greatly extend circulation time of drug delivery vehicles, some disadvantages 
such as immunological reactions, changes in pharmacokinetic behavior, non-
biodegradability, and toxicity of side-products still exist [67].  Recently, Parodi et al. 
reported a clever way to circumvent the problem of immediate detection and clearance 
by the immune system without the use of PEG.  They cloaked silica nanoparticles with 
freshly harvested leukocyte membranes, which were able to retain critical 
transmembrane proteins that allowed them to selectively bind inflamed ECs  [68].   
 
1.5 Thesis Hypothesis and Experimental Strategy 
  Motivated by the current need to address limitations in the treatment and 
diagnosis of atherosclerosis, we decided to design a leukocyte-inspired liposomal based 
drug delivery system that directly targeted inflamed endothelium.  We hypothesized that 
increased diffusivity of targeting antibodies to VCAM1 and E-selectin, facilitated by 
increased liposomal membrane fluidity, may improve the targeting efficiency of 
liposomes.  Our experimental strategy to test this dissertation’s hypothesis developed 
into three separate aims; a brief description of each aim is provided below.  
  In aim 1, we characterized both our liposomal and endothelial cell systems to set 
a foundation for experiments in aim 2.  We hypothesized that the lateral diffusivity of 
antibodies aVCAM1 and aE-selectin increased with increasing liposomal membrane 
fluidity.  Based on these results, we were able to lay the groundwork that allowed us to 
examine the interaction between liposome and ECs as specified subsequently aim 2.  
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  Aim 2 focused on evaluating liposomal targeting efficiency in vitro.  We explored 
the question of how lateral diffusion of antibodies affected liposome targeting.  As a 
result, we also investigated how low antibody surface densities and membrane fluidity 
played a role in EC binding and uptake. 
  The driving hypothesis of aim 3 was to evaluate the liposome targeting efficiency, 
with low and high antibody diffusivities, in a small rodent model of atherosclerosis.   
However, we were only able to complete a preliminary in vivo study where we examined 
the biodistribution of antibody coupled-PEGylated liposomes in healthy mice.    
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Chapter 2.   
Endothelial Cell and Liposomal System Characterization 
2.1 Introduction 
  The endothelium represents an ideal target for intravenous drug delivery 
because it plays an important role in numerous diseases such as atherosclerosis, 
inflammation, ischemia, cancer, and it is the first barrier between the bloodstream and 
tissue [62].  Leukocyte recruitment is a fundamental part of the inflammation process.  
Leukocytes are able to localize and extravasate thanks to the redistribution of various 
cell adhesion molecules, namely E-selectin, VCAM1, and ICAM1, from storage granules 
to the surface of vascular endothelial cells [56].   
  It is widely known in the field of endothelial cell biology, there are a number of 
molecules, which include interleukin-1, TNF-α, TNF-β, interferons, interleukin-2, 
interleukin-4, interleukin-6, and transforming growth factor-β (TGF-β) that stimulate the 
production of surface EC adhesion molecules [54,69].  Due to the myriad of studies 
present which have reported the use of different cytokine types, concentrations, and 
treatment times, we sought to characterize specific EC response to IL-1α and TNF-α in 
order to establish a good in vitro model to test the role liposome membrane fluidity plays 
in a targeted, drug delivery liposomal system. 
Membrane fluidity is an important aspect in both cells and artificial membranes 
i.e. vesicles.  It is now well known that components, such as flavonoids [70] and 
cholesterol [71], as well as the oxidation of unsaturated lipids [72] increase lipid 
membrane rigidity.  Although the physical properties of DOPC and DSPC have been  
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previously characterized [73], the physical properties of our formulations, which include 
5 mol % of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-dodecanoyl (N-dod-PE) 
have not been fully examined.   
In this aim, we determined how protein expression profiles of EC adhesion 
molecules changed as a function of cytokine type, dose, and treatment time.  We 
focused on characterizing the antibody-lipid conjugation efficiency and on quantifying 
the antibody surface densities.  Finally, we characterized two liposome formulations by 
measuring their lipid anisotropy and lateral diffusivity to quantify membrane 
characteristics important in targeting liposomes.  This body of work provided a strong 
platform for succeeding in  vitro experiments and enabled us to distinguish the 
differences between the physical properties of the two lipid formulations being tested. 
 
2.2 Materials and Methods 
2.2.1 Endothelial Cell Culture 
Human umbilical vein endothelial cells (HUVECs) were grown in endothelial 
growth medium-2 (EGM-2) with supplements as described by the distributor (Lonza, 
Allendale, NJ).  Cells were maintained at 37 °C in a humidified incubator with 5% CO2 
and used for experiments at passages 2 - 3.  Growth medium was changed the day 
after cell seeding and every other day thereafter.  
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2.2.2 Endothelial Cell Gene Expression 
HUVECs were seeded in 12 well plates and grown to confluence in EGM-2 
media with 2% FBS.  Cells were treated with 1, 10, or 25 ng/ml of TNF-α (Sigma 
Aldrich) or IL-1α (R&D Systems, Minneapolis, MN, USA) at 1, 5, or 10 ng/ml for 2, 4, 6, 
12, or 24 h.  Experiments were done in triplicate, and controls were performed with no 
cytokine treatment.  Total RNA was isolated from cells using a Qiagen RNeasy Mini Kit 
following the manufacturer’s procedures (Qiagen, Valencia, CA, USA).  The cells were 
lysed immediately after each incubation time point.  Quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) was performed on a 7300 real-time PCR system 
using the Taqman method (Applied Biosystems, Carlsbad, CA, USA).   An endogenous 
control of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used, and 
evaluations were done in triplicate.  All primers were obtained from Applied Biosystems.  
Relative expression levels of VCAM1, E-selectin, and ICAM1 were assessed.  
2.2.3 VCAM1 and E-selectin Immunostaining 
ECs (2 x 10
5 cells) were seeded on 18 x 18 mm
2 coverslips in 6-well plates with 2 
ml media (VWR, West Chester, PA) and cultured overnight at 37 °C. Cells were 
incubated with IL-1α at 5 ng/ml or TNF-α at 20 ng/ml in fresh EGM-2 media the next day 
for 6 h or 24 h. After medium was removed, cells were rinsed with PBS three times and 
fixed with 4% formaldehyde in PBS at RT for 15 min followed by washing with PBS. 
Samples were blocked with 1% BSA in PBS (1% BSA) at 4 °C for 1 h. Samples were 
then stained with aVCAM1 and aE-selectin mAbs (10 ng/ml in 1% BSA) at 4 °C for 2 h 
and rinsed with PBS. Samples were incubated with FITC-conjugated goat anti-mouse  
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(1:300), TRITC-conjugated rabbit anti-sheep secondary mAbs (1:300) and Hoescht 
33258 (1:1000) at 4 °C for 1 h followed by washing with PBS. Samples were then 
mounted on microscope slides (3” x 1”, VWR, Radnor, PA) with VECTASHIELD® 
mounting medium (Vector Laboratories, Burlingame, CA), and sealed. Samples were 
examined under an Axiovert 200 inverted fluorescent microscope (Carl Zeiss, 
Thornwood, NY) equipped with a Hammamatsu CCD camera (Bridgewater, NJ).  Digital 
images were captured with AxioVision digital image processing software (Zeiss). 
2.2.4 VCAM1 and E-selectin Expression  
VCAM1 and E-selectin expression by ECs was evaluated by flow cytometry after 
1, 6, 12, and 24 h incubations with either IL-1α (5 ng/ml) or TNF-α (25 ng/ml).   
Quantification of the density of molecules on the surface was determined using 
Quantum™ Simply Cellular® microbeads. After ECs were activated with IL-1α or TNF-
α, 10
6 cells were collected from a 6-well plate, spun down, and resuspended with ice 
cold 1% BSA. ECs were rinsed 3 times through suspension-spin cycles and blocked 
with 1% BSA for 30 min in an ice bath. ECs were incubated with mouse anti-human 
VCAM1 and sheep anti-human E-selectin mAbs (1 ml, 10 ng/ml) for 30 min in an ice 
bath. After rinsing with 1% BSA 3 times to remove free mAbs, ECs were stained with 
FITC-conjugated goat anti-mouse and TRITC-conjugated rabbit anti-sheep secondary 
antibodies for 30 min in an ice bath. ECs were finally rinsed with 1% BSA three times, 
resuspended in PBS, and analyzed by flow cytometry. 
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2.2.5 Measurement of Lipid Concentration  
The concentration of lipid in solution was determined by a phosphate assay as 
previously described [74]. Briefly, a diluted liposome sample was ashed with 0.2 ml 
sulfuric acid (10% v/v) at 200°C for 1 h, followed by addition of 50 µl hydrogen peroxide 
(30% v/v) and further heating at 200°C for 40 min. After the sample was cooled down to 
room temperature, 480 ml deionized water and 0.5 ml of color reagent (0.5% w/v 
ammonium molybdate, 2% w/v ascorbic acid) were added to each sample followed by 
heating at 45°C for 20 min. The samples were read at 820 nm using a SpectraMax Plus 
384 spectrophotometer (Molecular Devices, Sunnyvale, CA). A calibration curve was 
prepared with known phosphate quantities.  
2.2.6 Antibody Surface Characterization  
To determine the antibody density of aVCAM1 and aE-selectin, 2 μm borosilicate 
glass beads (Duke Scientific, Palo Alto, CA) were thoroughly washed three times in 
ethanol and water each through centrifugation-suspension cycles.  Microbeads were 
suspended in a solution of 4% hydrogen peroxide and 4% ammonium hydroxide and 
incubated at 80 °C for 10 min, followed by a 10 min incubation at 80 °C in 4% hydrogen 
peroxide and 0.4 M HCl.  Microbeads were washed 3 times after each incubation and 
immersed in PC:N-dod-PE (95:5) liposomes at the end.  Liposomes and microbeads 
were agitated for 6 h and washed through centrifugation–suspension cycles to separate 
excess free liposomes.  Conjugation of different ratios of FITC-conjugated aE-selectin, 
PE-conjugated aVCAM1, and FITC-conjugated IgG1 (nonspecific binding control) to 
microbeads was performed using EDC/NHS chemistry.  Fluorophore labeled primary 
antibodies were separated using suspension–spin cycles.  The density of aE-selectin  
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and aVCAM1 conjugated to the microbeads was determined with reference to Quantum 
Simply Cellular microbeads (Bangs Laboratory, Inc., Fishers, IN), which have defined 
numbers of antibody binding site per bead.  In addition, confocal microscopy of 
microbeads conjugated with FITC-conjugated aE-selectin, PE-conjugated aVCAM1, and 
FITC-conjugated IgG1 was performed in order to verify conjugation prior to evaluation 
with flow cytometry. Samples were examined under a Zeiss LSM710 upright confocal 
microscope (Carl Zeiss, Thornwood, NY).   
2.2.7 Fluorescence Polarization 
A 1:200 mol Bodipy® FL (Life Technologies/Thermo Fisher Scientific, Grand 
Island, NY):lipid was added to the different lipid mixtures of 1,2-di-(9Z-octadecenoyl)-sn-
glycero-3-phosphocholine:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-dodecanoyl 
(DOPC):(N-dod-PE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC):N-dod-PE as 
well as pure DOPC and DSPC.  Lipid mixtures were dried under a nitrogen stream and 
liposomes were prepared as mentioned in the previous section.  The final lipid 
concentration was kept at 1 mM.  Fluorescence polarization was measured at 22 ºC and 
37 ºC at excitation wavelength of 500 nm using a SpectraMax Gemini XS plate reader 
(Molecular Devices, Sunnyvale, CA).  Fluorescence anisotropy (A) values were 
calculated using the equation below:  
  	
 ∥   
 ∥    
                (2.1) 
where I∥  and I   correspond to the fluorescence intensities in the parallel and 
perpendicular directions, respectively, with respect to the polarized excitation wave.  
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2.2.8 Preparation of Supported Lipid Bilayers 
Supported lipid bilayers (SLBs) were prepared as described previously [75].   
Briefly, small unilamellar vesicles were prepared via extrusion as mentioned previously.  
Lipid films were dried under nitrogen gas and rehydrated with Tris-HCl buffer (10 mM 
Tris, 150 mM NaCl, 2 mM CaCl2, adjusted with HCl to pH 7.5).  The final lipid 
concentration was kept at 1 mg/ml.  To induce fusion, glass bottom dishes were cleaned 
by sonicating for 10 min subsequently in 3 M NaOH, 100% ethanol, and ultra pure 
distilled water.  The glass bottom dishes were then dried and exposed to air plasma 
(Plasma System Femto PCCE, Diener Electronic) at maximum power for 1.5 min to 
produce a hydrophilic surface.  A 1:20 liposome:Tris-HCl buffer volume ratio were 
deposited onto the clean glass surface and incubated for 1 h.  After 1 h, excess unfused 
liposomes were removed by carefully washing with ultrapure water.  Bilayers were kept 
hydrated at all times.   
2.2.9 Fluorescence Recovery After Photobleaching (FRAP) 
FRAP studies were conducted with a Zeiss LSM710 upright confocal microscope 
utilizing the 561 nm laser (Carl Zeiss, Thornwood, NY) and a 63X water immersion 
objective.  Digital 2D images were captured and analyzed with Zen 2012 digital image 
processing software (Zeiss).  Further FRAP analysis was done with ImageJ and Matlab.  
SLBs were labeled with 0.5 mol% rhodamine conjugated DOPE.  A circular region of 20 
nm in diameter was photobleached for 0.04 s after initially monitoring bilayers for 0.15 s 
and recovery was monitored for a total of 4.5 s.  A total of 20 regions were 
photobleached (5 per sample).  Frame size was set to 4.32 µm by 4.32 µm or 48 x 48 
pixels (0.09 µm/pixel).  Frames were acquired every 0.04 s.  Laser was utilized at 50%  
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power to acquire images and further increased to 100% when photobleaching the lipid 
bilayers.  All photobleaching settings remained the same for all samples.  Images were 
normalized by dividing the post-bleach fluorescence intensities by the first pre-bleach 
intensity.   
 
2.3 Results  
2.3.1 Gene Expression Profiles of Cell Adhesion Molecules 
  As a way to optimally reproduce inflammatory conditions in vitro, endothelial cells 
were exposed to different cytokines at various concentrations and incubation times.   
VCAM1, E-selectin, and ICAM1 are cell adhesion molecules known to be upregulated 
on the surface of endothelial cells when immersed in an inflammatory environment.  The 
HUVEC gene expression profiles of VCAM1, E-selectin, and ICAM1 were determined 
as shown below in Figures 2.1 and 2.2 [76].  ECs were exposed to 1, 10, and 25 ng/ml 
of TNF-α for 2, 6, and 24 h and then harvested and lysed.  As can be seen on Figure 
2.1  (A), VCAM1 gene expression increased with increasing exposure time at all 
cytokine concentrations, but peaked after 24 h exposure to 25 ng/ml of TNF-α.  Both E-
selectin and ICAM1 gene expression, as shown in Figure 2.1 (B) and (C), respectively, 
followed this exact same trend having their maximum expression levels after 24 h 
exposure to TNF-α.  HUVECs were also exposed to 1, 5, and 10 ng/ml of IL-1α.  
VCAM1 gene expression was highest after 6 h of exposure to the cytokine at all three 
concentrations as shown in Figure 2.2 (A).  E-selectin gene expression followed the 
same trend as VCAM1, having highest expression levels after a 6 h exposure to the  
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cytokine (Figure 2.2 (B)).  E-selectin gene expression levels also reached a maximum 
when exposed to 5 ng/ml of IL-1α.  ICAM1 gene expression exhibited the lowest levels 
of all three cell adhesion molecules.  Activation of HUVECs with 5 ng/ml IL-1α for 6 h 
provided the maximum upregulation of all three cell adhesion molecules.  Based on 
these results, we chose to focus only on VCAM1 and E-selectin with the remainder of 
experiments going forward. 
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Figure 2.1: HUVEC gene expression profiles after exposure to TNF-α. Profiles of 
(A) VCAM1, (B), E-selectin, and (C) ICAM1 after treatment with 1-25 ng/ml TNF-α for 2 - 
24 h. 
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Figure 2.2: HUVEC gene expression profiles after exposure to IL-1α. Profiles of (A) 
VCAM1, (B), E-selectin, and (C) ICAM1 after treatment with 1-10 ng/ml IL-1α for 2 - 24 
h. 
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2.3.2 Protein Expression of VCAM1 and E-selectin 
  After the gene expression profiles of the three main cell adhesion molecules 
present in inflammation were examined, we decided to evaluate the expression of 
VCAM1 and E-selectin over the course of 24 h.  The results are shown below in 
Figures 2.3 and 2.4.  HUVECs were activated with 25 ng/ml TNF-α and 5 ng/ml IL-1α.  
Flow cytometry results showed VCAM1 expression increased consistently with 
increasing activation times.  E-selectin expression peaked after the 6 h activation time 
with both cytokines and declined thereafter.  Upregulation of VCAM1 and E-selectin was 
also qualitatively evident after immunostaining ECs at the 6h and 24 h incubation points.  
Given that we confirmed 5 ng/ml of IL-1α for 6 h produced the highest upregulation of 
both VCAM1 and E-selectin, we decided to perform all subsequent in vitro experiments 
under these conditions.   
 
 
 
 
 
Figure 2.3: Time-course expression of VCAM1 and E-selectin on TNF-α and IL-1α 
activated ECs.  ECs were activated with either TNF-α or IL-1α for various durations.   
Expression of VCAM1 (A) and E-selectin (B) was determined using flow cytometry as a 
function of time.  Error reported is standard error with n = 3. 
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Figure 2.4: VCAM1, E-selectin, and IgG1 isotype control immunostaining for TNF-α 
and IL-1α-activated and non-activated ECs. ECs were activated with TNF-α and IL-
1α for 6 h (A) and 24 h (B), then fixed, and immunostained with aVCAM1 and aE-
selectin. Scale bar, 10 µm. 
A 
B  
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2.3.3 Characterization of Lipid Coated Glass Microbeads  
  Lipid coated microbeads were used to quantify the antibody surface density of 
liposomes.  Borosilicate glass microbeads were coated with a lipid bilayer conjugated 
with fluorescently tagged aVCAM1 and aE-selectin.  In this manner, the number of 
antibody molecules on the surface of the beads was calculated by detecting the mean 
fluorescence intensity of each bead population via flow cytometry.  The lipid 
concentration of liposomes used to coat the microbeads was determined by a 
phosphate assay.  A standard calibration curve, shown below in Table 2.1 and Figure 
2.5, correlating the phospholipid amounts to absorbance units was used to calculate 
final lipid concentration after the last extrusion step.  Once the concentration was 
known, the correct concentration of liposomes was added to the glass microbeads to 
begin the coating process.  It should be noted that all lipid concentrations were 
calculated in this manner for each experiment involving liposomes throughout all aims.   
Table 2.1: Phosphate Assay Standard Calibration Curve.   
Volume of Lipid (µl)  Phosphate Concentration 
(nmol) 
Average Absorbance 
(A.U.) 
0  0 0.03 
2  6.4 0.20 
4  12.7 0.42 
8  25.4 0.79 
10  31.8 1.02 
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Figure 2.5: Determination of lipid concentration utilizing a phosphate assay.   
Sample of a standard calibration curve used to correlate absorbance values to known 
lipid amounts in order to calculate concentrations of liposome samples using a standard 
linear regression equation.  
  
In order to corroborate vesicle rupture and successful coating, glass microbeads 
were agitated with liposomes containing 0.5% rhodamine-DOPE and imaged after 
removing excess liposomes.  Complete coverage of microbeads by lipid membranes 
was evident and can be observed in Figure 2.6 (A).  A new batch of microbeads was 
lipid-coated and conjugated with PE-conjugated aVCAM1 (Figure 2.6. (B)) and FITC-
conjugated aE-selectin (Figure 2.6. (C)).  The images confirmed not only successful 
lipid coating of microbeads, but also successful conjugation of both antibodies. 
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2.3.4 Quantification of Antibody Surface Densities 
Antibody density characterization was determined by using standardized 
microbeads that have calibrated binding sites on their surfaces and allow the user to 
correlate fluorescence intensity to number of bound antibody molecules.  In light of 
investigating the effect of liposomal membrane fluidity on EC uptake and binding, we 
characterized our two lipid formulations, 95:5 DOPC:N-dod-PE and 95:5 DSPC:N-dod-
PE, composed of unsaturated and saturated lipids, respectively (Figure 2.7 (A) and 
(B)).  The average antibody density at the maximum concentration of aE-selectin and 
aVCAM1 averaged 1108 ± 119 and 940 ± 394 molecules/µm
2 for DOPC coated beads, 
and 1040 ± 228 and 1449 ± 261 for DSPC coated beads.  At the lowest concentration of 
antibodies, only 148 ± 15 of aE-selectin and 64 ± 10 of aVCAM1 molecules/µm
2 were 
present on DOPC coated beads while only 108 ± 62 aE-selectin and 142 ± 24 aVCAM1 
molecules/µm
2 were present on DSPC coated beads.  These values were converted to 
the number of antibody molecules/liposome and are shown on Table 2.2. Our results 
were consistent with previously reported antibody surface densities on drug delivery 
vehicles [65,77,78]. 
DSPC exhibited a stronger PE-VCAM1 signal compared to DOPC conjugated 
with PE-VCAM1.  However, only mean fluorescence intensities conjugated with 0.5% 
PE-VCAM1 between these two conditions were found to be significantly different (p < 
0.05).  The differences between the remaining concentrations were found to not be 
statistically significant (p > 0.05).  DSPC conjugated with PE-VCAM1 also exhibited 
higher fluorescence values compared to DSPC conjugated with FITC-E-selectin, but 
none of the mean fluorescence intensities were found to be significantly different (p >  
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0.05).  Additionally, one cannot directly compare antibody binding capacities if a 
different fluorophore is utilized between conditions due to the difference in fluorophore 
size and brightness [79].  In this case, we were forced to utilize two different 
fluorophores, FITC and PE, simultaneously because we needed to quantify the 1:1 
VCAM1:E-selectin DOPC and DSPC conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Characterization of Antibody Surface Density.  DOPC (A) and DSPC (B) 
coated borosilicate glass beads were conjugated with different antibody concentrations 
A 
B  
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Figure 2.7 (Continued): and ratios and quantified via flow cytometry.  Error bars are 
reported as standard deviation with n = 3. 
 
Table 2.2: Calculation of Number of Antibody Molecules per Liposome.  The 
average number of antibody molecules per liposome was converted from the values 
shown in Figure 2.7.  Lipid coated glass beads were conjugated with 1:1 PE-labeled 
aVCAM1: FITC-labeled aE-selectin simultaneously and assayed by flow cytometry twice 
in order to measure both PE and FITC signals.  It was assumed liposomes had a 
diameter of 100 nm. 
Average Standard  Deviation 
DOPC DSPC DOPC DSPC 
0.5% IgG   1 1  1  1 
1% IgG   2 1  1  1 
2.5% IgG   3 2  1  1 
5% IgG   4 3  1  1 
10% IgG   7 5  1  2 
100% IgG   10 7  2  2 
0.5% aE-selectin   5 3  1  2 
1% aE-selectin   7 5  1  3 
2.5% aE-selectin   12 7  3  4 
5% aE-selectin   17 12  3  5 
10% aE-selectin   23 19  3  6 
100% aE-selectin   35 33  4  7 
0.5% aVCAM1   2 4  1  1 
1% aVCAM1   4 5  1  1 
2.5% aVCAM1   8 10  2  3 
5% aVCAM1   12 14  4  1 
10% aVCAM1   25 27  9  3 
100% aVCAM1   30 46  12  8  
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Table 2.2 (Continued). 
0.5% 1:1 FITC-labeled aE-selectin  2 2  1  1 
1% 1:1   3 3  1  1 
2.5% 1:1   5 4  1  1 
5% 1:1   7 6  1  2 
10% 1:1   11 9  3  1 
100% 1:1   13 14  2  2 
0.5% 1:1 PE-labeled aVCAM1   1 4  1  1 
1% 1:1   2 4  1  1 
2.5% 1:1   4 6  1  1 
5% 1:1   7 7  2  1 
10% 1:1   11 11  3  2 
100% 1:1   17 29  5  5 
 
 
2.3.5 Characterization of Membrane Fluidity 
  Differences in membrane fluidity were assessed by fluorescence polarization as 
reported previously [80].  To determine membrane fluidity, the fluorescence intensity of 
a hydrophobic fluorophore that inserts itself within the lipid bilayer was measured.  We 
utilized the hydrophobic dye BODIPY® FL as our membrane probe.  Higher anisotropy 
values corresponded to decreased probe motion within the bilayer and hence increased 
membrane rigidity.  DSPC is a saturated lipid (Figure 2.8 (A)) that has a melting 
transition temperature (Tm) of 55 °C and it is therefore in the solid gel phase (Lβ) at 22 
°C and 37 °C.  On the other hand, DOPC is an unsaturated lipid (Figure 2.8 (B)) that 
has a Tm  of -20 °C and it is in the liquid crystalline phase (Lα) at these same 
temperatures.  Our fluorescence anisotropy results reflect the difference in both of these 
lipids’ phases (Figure 2.9).  The decrease in DOPC’s anisotropy values when N-dod- 
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PE, whose chemical structure is shown in (Figure 2.8 (C)), is introduced may indicate a 
higher fluidity is observed possibly due to imperfections in the lipid packing order of the 
membrane caused by the presence of phosphoethanolamines in the lipid composition 
[81]. The differences between 100% and 95:5 DSPC were determined to not be 
significant.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Chemical structures of lipids.  Chemical structures of unsaturated DOPC 
(A), saturated DSPC (B), and antibody lipid anchor N-dod-PE (C) are shown.   
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Figure 2.9: Characterization of Membrane Fluidity.  Fluorescence anisotropy values 
of both 100 mol% DOPC and DSPC (A) and DOPC:N-dod-PE and DSPC:N-dod-PE 
(95:5 mol:mol) (B).  Measurements were taken at 22°C and 37°C.  Error bars are 
reported as standard deviation with n = 3.   
A 
B  
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To further characterize membrane fluidity, a FRAP study was conducted with 
94.5:5 DOPC:N-dod-PE and 94.5:5 DSPC:N-dod-PE supported lipid bilayers (SLBs).  
SLBs were labeled with 0.5 mol% rhodamine conjugated DOPE.  Raw data were 
analyzed in ImageJ and Matlab.  Sample images and their intensity bleach depth 
profiles are shown in Figure 2.10.  Differences on bleach spots were observed between 
DOPC and DSPC bilayers.  Both sets of bleach depth data followed a Gaussian profile.  
Rhodamine-PE in DOPC bilayers showed a larger bleach radius and a shallower bleach 
depth.  In contrast, the bleach radius was narrower and deeper in DSPC bilayers, as 
expected.   
The mean intensity values in the bleached region vs. time were obtained via Zen 
digital image processing software.  Furthermore, these data were fitted to the Axelrod 
series solution for a Gaussian intensity profile, as previously reported [82,83]: 
      	   	∑
     
 !    
    1    1 
  
                                                                   (2.2) 
where A is a free parameter, K is the bleach depth, and   is the diffusion recovery time.  
FRAP data were fitted to the Axelrod equation using Matlab with the help of the routine, 
FRAPé (beta) developed by Sanii B et al.  Figures 2.11 and 2.12 show marked 
differences between diffusion kinetics of 95:5 DOPC and DSPC bilayers.  Fluorescent 
membrane probe, rhodamine-DOPE, was observed to have a fast recovery in DOPC 
bilayers, but not in DSPC bilayers.  Diffusion coefficients were calculated using   	
  
   
and averaged as shown in Figure 2.13.  Diffusion coefficients of rhodamine-DOPE in 
DOPC bilayers were found to be an order of magnitude higher than in DSPC bilayers.  
The 95:5 DOPC:N-dod-PE’s greater fluidity is confirmed by its fast recovery observed  
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within the 5 s interval; this correlates with previously reported data of unsaturated lipids 
[84].  95:5 DSPC:N-dod-PE SLBs on the other hand, were unable to recover within this 
time frame.  The limited diffusivity of the probe molecules in 95:5 DSPC:N-dod-PE 
bilayers was expected as the experiments were all conducted at room temperature, 
which is below DSPC’s Tm.  The differences between membrane fluidities were evident; 
this correlated with previous reports of FRAP studies involving unsaturated and 
saturated lipid bilayers [85–87]. 
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Figure 2.12: Sample FRAP study of DSPC supported lipid bilayers. (A) – (C) show 
representative frames of a DSPC FRAP experiment. Time was set to 0 at the first post-
bleach image and the bleached area was monitored for approximately 4.5 s. Scale bar, 
0.5 μm.  Normalized intensity data were fitted to the Axelrod equation and diffusion 
coefficients were calculated using Matlab (C). 
 
t = 4.5 s  t = - 0.2 s  t = 0 s 
D  E  F  
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Figure 2.13:  Average diffusion coefficients of rhodamine-DOPE in DOPC and 
DSPC supported lipid bilayers.  Diffusion coefficients indicate higher probe mobility in 
unsaturated DOPC bilayers (average D = 3.1 ± 0.9 µm
2/s) than in saturated DSPC 
bilayers (average D = 0.44 ± 0.22 µm
2/s).  Error bars are reported as standard 
deviation, n = 20.   
 
2.4 Discussion 
  Cytokine concentrations and exposure times were optimized in order to establish 
an optimal in vitro model of inflammation at the endothelial cell level.  Gene expression 
analysis of VCAM1, E-selectin, and ICAM1, three of the most important cell adhesion 
molecules upregulated during inflammation were performed [56,88].  Results showed 
that a 24 h exposure of ECs to 25 ng/ml of TNF-α increased gene expression levels of 
all three cell adhesion molecules to a maximum.  In addition, a 6 h exposure to 5 ng/ml  
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of IL-1α produced the highest gene expression levels of all three molecules.  ICAM1 
gene expression was significantly lower than VCAM1 and E-selectin expression upon 
exposure to all three different concentrations of each cytokine.  ICAM1 gene expression 
levels were the lowest among all three molecules tested.  Furthermore, ICAM1 is known 
to be constitutively expressed at low levels on the surface of ECs [89].  Therefore, we 
decided to focus only on VCAM1 and E-selectin as we moved forward with experiments.   
  The surface expression of VCAM1 and E-selectin on TNF-α and IL-1α-activated 
ECs was quantified as a function of time.  The expression of VCAM1 and E-selectin was 
affected by the duration of exposure, but not cytokine type (no statistical difference, p > 
0.05).  The density of E-selectin peaked at 6 h by ten-fold and nine-fold relative to non-
activated ECs for both TNF-α and IL-1α, respectively.  VCAM1 expression increased 
constantly with time; it increased by three- and two-fold relative to expression on non-
activated ECs after 24 h of exposure to TNF-α and IL-1α, respectively.  Upregulation of 
VCAM1 and E-selectin by the inflammatory cytokines at 6 h and 24 h was also 
confirmed by immunostaining.   
Antibody surface density of vesicles was characterized by conjugating antibodies 
onto lipid coated glass microbeads and analyzing with flow cytometry.  We established 
a phosphate assay to measure final liposome concentrations of vesicles utilized to coat 
the glass microbeads.  This assay was also used in all subsequent liposome 
preparations in order to quantify final concentrations before exposing ECs to liposomes.  
We verified successful coating of the microbeads and antibody conjugation to the lipid 
bilayer by confocal microscopy.  DOPC and DSPC coated beads conjugated with 
increasing amounts of PE-conjugated aVCAM1 and FITC-conjugated aE-selectin were  
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analyzed by flow cytometry.  We were able to construct an antibody concentration curve 
and indirectly quantify the number of antibody molecules per area.  At the maximum 
concentration of each antibody, there were approximately 1000 antibody molecules/µm
2 
regardless of the lipid utilized to coat the microbeads.  At the lowest concentration, 
roughly 100 antibody molecules/µm
2 were calculated to be present on the bead surface.  
No statistically significant differences were found between mean fluorescence 
intensities across conditions, except for DOPC and DSPC 0.5% PE-conjugated VCAM1.   
We calculated the theoretical maximum number of antibody molecules that could 
potentially be conjugated on the surface of each liposome.  To do our calculation we 
assumed the following: each liposome had  a diameter of 100 nm, each phospholipid 
had a phosphate head group area of 70 Å
2, which is the value that has been reported 
for DOPC [90], each antibody occupied an area of 100 nm
2, which is consistent with 
previous reports of IgG molecule gyration radii [91], and finally that all 5 mol % of N-
dod-PE molecules were localized in the outer bilayer.  Based on these parameters, we 
calculated that a maximum of 300 antibodies would be able to be conjugated on the 
surface of one liposome.  This number correlates with the data obtained, however, it 
should be noted the areas of the IgG antibody and N-dod-PE molecules were being 
approximated.  It is also very likely that only a fraction of the total number of N-dod-PE 
molecules incorporated into the outer bilayer and allowed its conjugation site to become 
available.  Neither N-dod-PE’s nor the antibody molecule’s precise configuration and 
orientation were controlled during the chemical conjugation reaction.  Efficient antibody 
immobilization is highly desirable in order to increase specificity and strength of  
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antibody-antigen binding and should be subject of further optimization of our liposomal 
system. 
We characterized membrane fluidity of unsaturated DOPC and saturated DSPC 
liposomes by utilizing a fluorescence polarization assay.  DOPC liposomes with and 
without N-dod-DOPE had significantly lower anisotropy levels compared to DSPC.  This 
trend was confirmed at both 22 °C and 37 °C.  We measured the diffusivity of a 
fluorescent probe in supported lipid bilayers composed of 94.5 mol % DSPC and 
DOPC, 5% N-dod-DOPE, and 0.5 mol % rhodamine labeled DOPE.  Our results 
corroborated our fluorescence polarization results and showed the fluorescent probe is 
able to quickly diffuse back to the photobleached spot in DOPC bilayers.  Diffusion of 
the probe back to the photobleached spot does not occur in DSPC bilayers.  
As a result of completing this aim, we were able to establish optimal cytokine 
concentrations and exposure times to elicit an inflammatory response in endothelial 
cells that produced high levels of VCAM1 and E-selectin cell surface expression.  The 
results of these experiments set the foundation of an optimal in vitro inflamed EC model 
to use as the basis of our liposome targeting experiments.  Our protein cell surface 
experiment results correlated with our qRT-PCR results, indicating gene expression of 
VCAM1 and E-selectin was comparable to the amount of protein present on the cell 
surface.  Since exposing ECs with 5 ng/ml of IL-1α for 6 h produced the highest VCAM1 
and E-selectin gene expression, we determined to use this protocol for all subsequent 
liposome targeting experiments.  Furthermore, completion of this aim allowed us to 
characterize important properties of our liposome system such as: lipid concentration, 
liposome-antibody conjugation efficiency, and liposome membrane fluidity.    
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Chapter 3. 
Effect of Liposomal Membrane Fluidity on Endothelial Cell Binding and Uptake 
3.1 Introduction  
Chronic inflammation is the underlying mechanism of atherosclerosis, governed 
by monocyte and T lymphocyte recruitment upon the upregulation of vascular cell 
adhesion molecule-1 (VCAM1), E-selectin, and intercellular adhesion molecule-1 
(ICAM1) on endothelial cell membranes [54,56]. These molecules enable the 
endothelium to bind and transport leukocytes from the bloodstream to diseased tissue 
[92,93], making it an attractive drug delivery target. We and others have proposed using 
molecules to target inflamed endothelium to localize drug and/or block leukocyte 
recruitment [94–96].  Traditionally, the focus has been to identify a single receptor-
ligand pair that will amplify vehicle localization in inflamed tissue relative to normal. 
However, the targeting paradigm has evolved; it has become more widely accepted that 
both the chemical and physical properties of drug delivery vehicles drive endothelial cell 
binding and internalization [97]. 
Chemical modification of liposomes with antibodies or ligands has shown 
promise in increasing binding towards cells that overexpress a particular receptor 
[98,99].  In vitro endothelial cell (EC) overexpression of VCAM1, ICAM1, and E-selectin 
by  cytokine activation is analogous to gene expression profiles observed in in  vivo 
inflammation [69].  We quantified the surface density of VCAM1, ICAM1, and E-selectin 
in normal and cytokine-activated ECs.  We demonstrated that liposomes that 
complement the ratio of ICAM1:E-selectin or VCAM1:E-selectin enhanced cytokine- 
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activated EC uptake [65,100].  Several papers have adopted a dual targeting strategy to 
improve their targeting results [101,102].  Nonetheless, the challenge in the field is to 
increase liposome-cell binding prior to clearance by the reticulo-endothelial system 
(RES). 
Methods to improve liposome binding and uptake include increasing the surface 
concentration and altering the surface chemistry [103,104].  Optimizing the antibody 
surface density is a balance between cell targeting and immune recognition; high 
antibody densities lead to a faster rate of liposome clearance from circulation, above 70 
- 80 µg antibody/µmol phospholipid [78,105], which would correspond to approximately 
30 to 40 antibody molecules per liposome with a 100 nm diameter [78].   Additionally, 
the use of multiple antibodies [106,107] and multivalent polymers [108] have shown 
advantages over single antibody or monovalent approaches.  These findings, however, 
may be dependent on whether the targeting ligand is bound to a liquid phase liposome, 
gel phase liposome, or nanoparticle.  
Identification of VCAM1 and E-selectin localization within lipid rafts - saturated 
lipid-rich microdomains on the cell membrane - spurred our interest to identify the 
contribution of the lipid membrane in ligand-receptor adhesion.  Saturated lipids often 
exist in the gel phase at physiological temperature, resulting from their ability to closely 
pack with like molecules, whereas unsaturated molecules that have kinks in their carbon 
chain exist in the liquid phase.  It has also been shown that liposomes composed of 
neutral, saturated lipids are cleared from the bloodstream more rapidly than unsaturated 
liposomes due to plasma protein affinity for hydrophobic domains, characteristic of 
saturated lipid membrane packing defects [109].  Molecules, such as cholesterol and  
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hydrophobic drugs, that partition into liposomal membranes can affect lipid bilayer 
elasticity [110].  Theoretical models of the mechanics of receptor-mediated endocytosis 
and cell adhesion support that membrane rigidity plays an important role in 
internalization and binding [111,112].  
In this report, we investigated the synergy between both chemical and 
mechanical properties of liposomes to ascertain quantitative metrics with which to 
engineer EC binding and uptake.  Single parameters have been independently tested, 
such as size, shape, and targeting moiety.  However, the impact of each of these 
components relative to another is unclear.  Little has been done on the mechanics of 
membrane though it is clear that small changes in liposome formulation can result in 
significant changes in bilayer mechanics.  Therefore, we decided to explore the effect 
liposomal membrane fluidity and antibody diffusivity had on the efficiency of EC 
targeting.  We determined an optimal formulation for binding activated and non-
activated endothelial cells. We demonstrated that liposome binding and internalization 
are significantly enhanced by these metrics. 
 
3.2 Materials and Methods 
3.2.1 Liposome Preparation 
Unilamellar liposomes were prepared by the extrusion method as previously 
described [13]. A mixture of DOPC:N-dod-PE or DSPC:N-dod-PE (95:5 mol%) (Avanti 
Polar Lipids, Alabaster, AL) in chloroform was dried under a nitrogen stream. The lipids 
were then dissolved in a mixture of DMSO:EtOH (7:3 v/v). Lipid mixtures (1 ml) were  
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injected in 6 ml 10 mM N-[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid 
(TES) (Sigma Aldrich, St. Louis, MO) buffer (pH 7.4) with or without rhodamine-
conjugated dextran (1 mg/ml) while being agitated at 1000 rpm with a stir bar to yield 
8.33 mM lipid. The multilamellar vesicles were subjected to 10 freeze-thaw cycles 
(utilizing liquid nitrogen) prior to extrusion. Large unilamellar vesicles were prepared by 
utilizing a LIPEX
TM extruder (Northern Lipids, Burnaby, BC, Canada). Vesicles were 
extruded 10 times through two 100 nm polycarbonate membranes (Whatman 
Nucleopore 25 mm track-etched membranes, GE Healthcare Biosciences, Piscataway, 
NJ). Dextran-encapsulated liposomes were dialyzed against 10 mM TES buffer using a 
Slide-A-Lyzer dialysis cassette (MWCO 20 kDa, Pierce Biotechnology, Inc., Rockford, 
IL) overnight at room temperature (RT). Liposome size was measured by dynamic light 
scattering on a ZetaPALS analyzer (Brookhaven Instruments, Corp., Holtsville, NY) in 
10 mM TES buffer (pH 7.4).  The exact same procedure was repeated for double 
labeled liposomes with the exception of the addition of 2 mol% NBD-DOPE dissolved in 
ethanol and added as 1% volume.  NBD-DOPE was added to the liposomes after 
extrusion to ensure only the outer membrane would contain the fluorescent lipid. 
The concentration of lipid in solution was determined by a phosphate assay as 
previously described [74]. Briefly, a diluted liposome sample was ashed with 0.2 ml 
sulfuric acid (10% v/v) at 200°C for 1 h, followed by addition of 50 µl hydrogen peroxide 
(30% v/v) and further heating at 200°C for 40 min. After the sample was cooled down to 
room temperature, 480 ml deionized water and 0.5 ml of color reagent (0.5% w/v 
ammonium molybdate, 2% w/v ascorbic acid) were added to each sample followed by 
heating at 45°C for 20 min. The samples were read at 820 nm using a Spectramax Plus  
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384 spectrophotometer (Molecular Devices, Sunnyvale, CA). A calibration curve was 
prepared with known phosphate quantities.  
3.2.2 Liposome-Antibody Conjugation  
  Antibodies were conjugated to liposomes via the N-dod-PE anchor. EDC (3 mg) 
and NHS (4 mg) (Sigma Aldrich, St. Louis, MO) were added to 8.33 mM lipid 
(liposomes) in 10 mM TES buffer (pH 7.4) and incubated for 6 h at room temperature.  
Excess EDC and NHS were removed using Slide-a-Lyzer dialysis cassettes (20 kDa 
MWCO). IgG1 isotype monoclonal antibody (mAb) (100 mol%, non-specific binding 
control) or mixtures of aVCAM:aE-selectin mAbs (1:0, 0:1, and 1:1 molar ratios) were 
added to EDC-modified liposomes at a molar ratio of 1:1000 antibody:phospholipids and 
incubated overnight at room temperature.  All mAbs were purchased from R&D 
Systems (Minneapolis, MN). Free antibodies were separated using Float-a-Lyzer 
dialysis tubes (300 kDa, Spectrum Labs, Rancho Dominguez, CA) dialyzed against 10 
mM TES buffer at pH 7.4.   
3.2.3 Cell Culture 
Human umbilical vein endothelial cells (ECs) were grown in endothelial growth 
medium-2 (EGM-2) with supplements as described by the distributor (Lonza, Allendale, 
NJ). Cells were maintained at 37°C in a humidified incubator with 5% CO2 and used for 
experiments always at passage 4. Growth medium was changed the day after cell 
seeding and every other day thereafter.  
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3.2.4 Liposome Uptake by ECs 
Liposome binding and uptake was first assessed by incubating ECs with 
liposomes encapsulating rhodamine-dextran.  Incubations took place at 37°C for 1 h 
and 4 h.  Additionally, binding and uptake was further assessed by incubating ECs with 
double labeled liposomes encapsulating rhodamine-dextran and incorporating NBD-
DOPE in the outer lipid monolayer.  Incubations took place at 37º C for 5 min, 30 min, 
and 1 h. 
Liposome binding and uptake by ECs was analyzed using flow cytometry as 
previously described [113,114].  ECs were seeded in 6-well plates (3 x 10
5 cells/well) 
and allowed to adhere overnight.  After activation with IL-1 (5 ng/ml) for 6 h, ECs were 
incubated for the various time points previously mentioned at 37°C with either dextran-
loaded only or dextran-loaded and NBD-DOPE-labeled: (1) nonspecific (IgG1) 
liposomes; (2) bare liposomes (no antibodies conjugated on liposome surface); and (3) 
liposomes conjugated with different ratios of aVCAM1:aE-selectin mAbs.  The dose 
concentration used was 1 μmol lipid/10
6 cells, as previously reported [115].  
In order to discern between liposome binding on EC surfaces and actual 
internalization by ECs, cells were exposed to cytochalasin D and dithionite (Sigma 
Aldrich, St. Louis, MO) as described previously [116].  Double labeled liposomes 
(rhodamine dextran-loaded and NBD-DOPE-labeled) were used in these experiments.  
Surface binding was isolated by blocking cellular internalization with cytochalasin D.  
During EC activation, cytochalasin D was added to EGM-2 (final concentration of 0.2 
μg/ml) containing IL-1 and incubated with cells 30 min prior to liposome incubations.  
At the end of the 6 h activation period, all wells were rinsed with 1X phosphate buffered  
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saline (PBS) (Life Technologies/Thermo Fisher Scientific, Grand Island, NY) and 
replaced with fresh EGM-2.  Internalization was measured separately from binding by 
utilizing the dithionite assay, which uses dithionite to quench NBD-DOPE’s fluorescence 
signal.  75 μl of dithionite solution (1 M Tris, pH 10) was added for 3 min to each well at 
the end of each liposome incubation period.  All wells were rinsed with 1X PBS to 
eliminate excess dithionite.   
Treated ECs were washed with PBS once again, harvested using a 0.25% 
trypsin solution, and collected in a polystyrene culture tube. Cells were further washed 
with ice cold PBS three times.  Binding and uptake data were acquired using an LSRII 
flow cytometry analyzer (BD Immunocytometry Systems, San Jose, CA) and analyzed 
with WEASEL software developed by WEHI (Parkville, Australia).  A total of 30,000 
events per sample were analyzed to generate each histogram.  The fold-over isotype 
value was calculated by dividing the mean fluorescence intensity for bare liposomes 
and liposomes conjugated with aVCAM1:aE-selectin by that of the IgG1 isotype-
conjugated liposomes.  After careful analysis of the data, we concluded it would be best 
to present data in its raw format instead of a normalized version.  Significant differences 
in liposome uptake were evaluated using a 2-way ANOVA statistical analysis.  A p value 
less than 0.05 was considered statistically significant.  
 
3.3 Results 
3.3.1 Liposome Binding and Uptake as a Function of Time 
  We investigated the uptake and binding of liposomes to ECs as a function of 
liposome membrane fluidity and incubation time.  Large unilamellar vesicles (LUVs) of  
 
56 
 
two different compositions: 95:5 DOPC:N-dod-PE and 95:5 DSPC:N-dod-PE were 
prepared via the extrusion method.  The average diameters of unconjugated DOPC:N-
dod-PE LUVs were 106 ± 5 nm, while the diameters of DSPC:N-dod-PE were 113 ± 5 
nm.  Diameter size was determined from dynamic light scattering.  Antibody density 
characterization was determined, as previously described in Chapter 2, by using 
standardized microbeads that have calibrated binding sites on their surfaces and allow 
for the user to correlate fluorescence intensity to number of bound antibody molecules.  
Confocal microscopy and flow cytometry analysis of lipid coated microbeads verified 
successful conjugation of antibodies.   
Liposome binding and uptake was measured by detecting the mean fluorescence 
intensity (MFI) values of rhodamine-labeled dextran encapsulated in liposomes. We 
evaluated the incubation of liposomes for 4 h and 1 h (Figure 3.1 and Figure 3.2, 
respectively) with non-activated an activated endothelial cells.  DOPC liposomes 
decorated with 1:1 and 0:1 aVCAM:aE-selectin had increased binding and uptake 
compared to their non-activated counterparts (Figure 3.1 (A)). This increase was 
statistically significant (p < 0.001).  DSPC liposomes bearing a 0:1 aVCAM:aE-selectin 
ratio on their surfaces also had significantly higher binding and uptake by activated ECs 
than liposomes exposed to non-activated ECs (Figure 3.1 (B)).  DSPC liposomes also 
displayed significantly greater binding and uptake by non-activated ECs than DOPC 
liposomes regardless of the antibody surface coating.  Furthermore, in the absence of 
surface antibody, bare DSPC liposomes exposed to non-activated ECs also had higher 
MFI values than DSPC liposomes incubated with activated ECs.  This difference was 
statistically significant (p < 0.05).    
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Figure 3.1: Flow cytometry evaluation of liposome binding and uptake by ECs 
after 4 h incubation.  Non-activated and activated ECs (IL-1α, 6 h) were treated with 
either DOPC:N-dod-PE (95:5 mol:mol) (A) or DSPC:N-dod-PE (95:5 mol:mol) (B)    
A 
B  
 
58 
 
Figure 3.1 (Continued): liposomes encapsulating rhodamine-labeled dextran and 
conjugated with various ratios of aVCAM1:aE-selectin mAbs for 4 h.  Results shown are 
raw mean fluorescence intensity (MFI) values.  Error bars are reported as standard 
deviation, n = 3.  Statistical significance was calculated using a two-way ANOVA test (*p 
< 0.05, **p < 0.01, and ***p < 0.001). 
 
We assessed binding and uptake at a shorter incubation time of 1 h with non-
activated and activated ECs again.  Both DOPC (Figure 3.2 (A)) and DSPC (Figure 3.2 
(B)) liposomes had significantly greater binding and uptake by activated ECs than by 
non-activated ECs when the liposomal surface displayed 1:1 and 0:1 aVCAM:aE-
selectin.  1:1 aVCAM:aE-selectin DOPC liposomes had significantly higher binding and 
uptake than DSPC conjugated with the same antibody ratio.  Our results also showed 
DSPC had significantly higher binding and uptake than DOPC regardless again of 
surface decoration when cells were not exposed to IL-1α.  DSPC binding and uptake 
values, however, are lower than the values observed during the 4 h incubation with non-
activated ECs.   
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Figure 3.2: Flow cytometry evaluation of liposome binding and uptake by ECs 
after 1 h incubation.  Non-activated and activated ECs (IL-1α, 6 h) were treated with 
either DOPC:N-dod-PE (95:5 mol:mol) (A) or DSPC:N-dod-PE (95:5 mol:mol) (B) 
A 
B  
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Figure 3.2 (Continued): liposomes encapsulating rhodamine-labeled dextran and 
conjugated with various ratios of aVCAM1:aE-selectin mAbs for 1 h.  Results shown are 
raw mean fluorescence intensity (MFI) values.  Error bars are reported as standard 
deviation, n = 3.  Statistical significance was calculated using a two-way ANOVA test (*p 
< 0.05, **p < 0.01, and ***p < 0.001). 
 
3.3.2 Liposome Binding and Uptake as a Function of Antibody Surface Density 
  We further investigated liposome binding and uptake as a function of antibody 
surface density.  Antibody concentrations in percent format refer to the percent of the 
total antibody concentration calculated to saturate the surface of the liposomes.  In 
other words, 100% of the antibody concentration refers to the total concentration of 
antibody required to bind all terminal carboxylic groups of N-dod-PE on the surface of 
the liposome.  Based on our previous 1 h and 4 h binding and uptake results, we 
decided to conjugate only aE-selectin onto liposomes and incubate for 1 h for all 
subsequent experiments.  Our results demonstrated DOPC’s binding and uptake was 
significantly higher even at concentrations as low as 2.5%, which approximately 
correspond to 371 ± 85 antibody molecules/µm
2 on the liposome surface (Figure 3.3 
(A)).  On the other hand, DSPC only showed a significant difference only when its 
surface was completely coated with antibodies (100%) (Figure 3.3 (B)).  However, 
DSPC liposomes had higher binding and uptake values regardless of the condition 
when cells were not activated (p < 0.05).   
  
 
61 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Liposome binding and uptake as a function of aE-selectin surface 
density.  Mean fluorescence intensity (MFI) values were determined by flow cytometry.  
Non-activated and activated (IL-1α, 6 h) ECs were treated for 1 h with DOPC:N-dod-PE 
(95:5 mol:mol) liposomes (A) and DSPC:N-dod-PE (95:5 mol:mol) liposomes (B) 
encapsulating rhodamine-labeled dextran.  The concentration of aE-selectin mAbs    
A 
B  
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Figure 3.3 (Continued): conjugated to the liposomal surface was also varied.  Error 
bars are reported as standard deviation, n = 3.  Statistical significance was calculated 
using a two-way ANOVA test (*p < 0.05, **p < 0.01, and ***p < 0.001). 
 
  In addition to conjugating increasingly higher E-selectin concentrations to the 
liposomal surface, we also conjugated IgG1 concentrations corresponding to the same 
amounts used in the aE-selectin experiments, and we performed the experiments under 
the same conditions so as to provide a control for non-specific binding and uptake.  No 
statistically significant differences were found in either DOPC (Figure 3.4 (A)) or DSPC 
(Figure 3.4 (B)) liposomes conjugated with the various concentrations of IgG1.  DSPC 
liposomes exhibited higher values than DOPC at all IgG1 mAbs concentrations once 
again (p < 0.05).  This time, nonetheless, the trend was apparent regardless of whether 
ECs were activated with IL-1α or not.   
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Figure 3.4: Liposome binding and uptake as a function of IgG1 surface density.  
Mean fluorescence intensity (MFI) values were determined by flow cytometry.  Non-
activated and activated (IL-1α, 6 h) ECs were treated for 1 h with DOPC:N-dod-PE (95:5 
mol:mol) liposomes (A) and DSPC:N-dod-PE (95:5 mol:mol) liposomes (B) 
encapsulating rhodamine-labeled dextran.  The concentration of control IgG1 mAbs  
A 
B  
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Figure 3.4 (Continued): conjugated to the liposomal surface was also varied.  Error 
bars are reported as standard deviation, n = 3.  Statistical significance was calculated 
using a two-way ANOVA test (*p < 0.05, **p < 0.01, and ***p < 0.001). 
 
3.3.3 Differentiating Between Binding and Uptake 
  We investigated pure cellular surface binding vs. cellular internalization of 
liposomes, separately, by the application of two different assays.  Liposomes were 
labeled with an NBD-conjugated lipid on their surface in addition to being loaded with 
rhodamine-labeled dextran.  To dissociate from uptake and only quantify EC surface 
binding, ECs were treated with cytochalasin D, a cellular internalization inhibitor, and 
shorter incubation time points were tested (Figure 3.5). Both fluorescent probes, NBD 
(Figure 3.5 (A)) and rhodamine (Figure 3.5 (B)), were detected simultaneously by the 
flow cytometer.  According to the membrane-bound NBD signal, DSPC liposomes 
reached their highest surface binding levels at 0.5 h then decreased.  DOPC liposomes, 
on the other hand, increased gradually and did not reach maximum surface binding until 
1 h.  Rhodamine fluorescence indicated the exact same trend and correlated to the 
surface binding that was observed when tracking membrane-bound NBD.  We 
performed cell surface binding control experiments with non-specific IgG1  and bare 
liposomes (Figure 3.6).  No significant differences were detected at any incubation time 
points. 
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Figure 3.5: Flow cytometry evaluation of cellular surface binding.  Activated ECs 
(IL-1α, 6 h) exposed to cytochalasin D (0.2 μg/ml, 30 min) were treated with NBD-DOPE 
membrane-labeled liposomes conjugated with aE-selectin and encapsulating 
rhodamine-labeled dextran.  Results shown are raw mean fluorescence intensity (MFI) 
values of NBD (A) and rhodamine (B).  Error bars are reported as standard deviation,  
A 
B  
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Figure 3.5 (Continued): n = 3.  Statistical significance was calculated using a two-way 
ANOVA test (*p < 0.05, **p < 0.01, and ***p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Cellular surface binding controls.  Activated ECs (IL-1α, 6 h) exposed to 
cytochalasin D (0.2 μg/ml, 30 min) were treated with NBD-DOPE membrane-labeled 
liposomes conjugated with aE-selectin and encapsulating rhodamine-labeled dextran.  
Results shown are raw mean fluorescence intensity (MFI) values of NBD (A) and 
rhodamine (B).  Error bars are reported as standard deviation, n = 3.     
A 
B  
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We examined cellular internalization via a dithionite assay, where dithionite was 
used to quench the NBD fluorescence signal.  Dithionite is cell membrane impermeable, 
thus most of the NBD fluorescence detected originated from the cell interior as NBD 
was quenched on the exterior of the cell.  Both DSPC and DOPC liposomes had 
increasing internalization as incubation time increased, and both saturated and 
unsaturated liposomes were internalized at a maximum level at 1 h time point (Figure 
3.7 (A)).  Rhodamine fluorescence detection (Figure 3.7 (B)) in this experiment did not 
reflect cellular internalization exclusively given that dithionite is supposed to only 
quench NBD.  We performed cellular internalization control experiments with non-
specific IgG1 and bare liposomes (Figure 3.8).  No significant differences were detected 
at any incubation time points, however, NBD fluorescence of DOPC and DSPC 
liposomes at 1 h was significantly higher than those observed with cell surface binding. 
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Figure 3.7: Flow cytometry evaluation of cellular internalization.  Activated ECs (IL-
1α, 6 h) exposed to dithionite (75 μl, 3 min) were treated with NBD-DOPE membrane-
labeled liposomes conjugated with aE-selectin and encapsulating rhodamine-labeled 
dextran.  Results shown are raw mean fluorescence intensity (MFI) values of NBD (A) 
and rhodamine (B).  Error bars are reported as standard deviation, n = 3.  Statistical  
A 
B  
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Figure 3.7 (Continued): significance was calculated using a two-way ANOVA test (*p < 
0.05, **p < 0.01, and ***p < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Cellular internalization controls.  Activated ECs (IL-1α, 6 h) exposed to 
dithionite (75 μl, 3 min) were treated with NBD-DOPE membrane-labeled liposomes 
conjugated with aE-selectin and encapsulating rhodamine-labeled dextran.  Results 
shown are raw mean fluorescence intensity (MFI) values of NBD (A) and rhodamine (B).  
Error bars are reported as standard deviation, n = 3.   
A 
B  
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3.4 Discussion 
  We have shown the effect of liposomal membrane fluidity on EC uptake and 
binding.  Increased membrane fluidity of liposomes decorated with relatively low 
antibody concentrations may lead to considerably high uptake and binding in ECs 
stimulated by IL-1α.  We prepared liposomes with fluid or gel phase lipids to test our 
antibody diffusivity hypothesis.  We functionalized the surface of liposomes by 
conjugating antibodies against cell adhesion molecules that are upregulated on the 
surface of ECs in an inflammatory environment.  We focused on targeting VCAM1 and 
E-selectin because these two molecules are temporally regulated by cytokines; this 
cytokine activation has been established to be reproducible [55,59].  In this aim, ECs 
were activated using IL-1α for 6 h.  In our previous aim, we characterized and 
determined that exposing ECs to 5 ng/ml of IL-1α for 6 h yielded the highest amount of 
VCAM1 and E-selectin expression on EC surfaces.    
  Activated ECs incubated with DOPC liposomes conjugated with a 1:1 and 0:1 
aVCAM1:aE-selectin for 4 h had increased mean fluorescence intensity (MFI) values.  
We had previously investigated DOPC liposomes with various aVCAM1:aE-selectin 
ratios and observed a complementary 1:1 aVCAM1:aE-selectin had the greatest binding 
and uptake [100].  In these studies, however, ECs were incubated with antibody labeled 
liposomes overnight.  Shortening the liposome incubation time from approximately 12 h 
to 4 h did not produce the same uptake and binding results.  Our results suggest that as 
incubation time is shortened from 12 h to 4h and further decreased to 1 h, E-selectin 
plays an increasingly important role in binding and uptake of liposomes, while VCAM1’s 
role declines.  The ratio of 0:1 aVCAM1:aE-selectin decorating both DOPC and DSPC  
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liposomes had significant uptake and binding by activated ECs (Figures 3.1 and 3.2).  
No significant differences were observed when liposomes were conjugated with a ratio 
of 1:0 aVCAM1:aE-selectin.  Further characterization of the temporal E-selectin surface 
expression after activation with IL-1α is needed.  Numerous studies have reported on 
the expression of E-selectin as a function of cytokine and cytokine activation [117], but 
the characterization of the temporal surface expression after activated ECs are no 
longer exposed to the cytokine has not been documented.  However, it can be inferred 
that the surface expression of E-selectin rapidly decays after the 6 h activation period 
since a decrease is observed even when the cells are still exposed to the cytokine.  This 
would potentially explain why binding and uptake increase with decreased incubation 
time.  We and others have shown the time-dependent expression of E-selectin peaks 
after 4 – 6 h of cytokine activation and then declines to basal levels within 24 h to 48 h 
[56,100].  The results reported in this aim indicate the use of aE-selectin alone is 
sufficient to achieve rapid localization of liposomes, within 1h, to activated ECs.  A 
possible clinical application where this scenario of rapid localization to injured tissue 
might be desirable is non-invasive molecular imaging of vulnerable atherosclerotic 
plaque [7]. 
  DSPC liposomes had significant binding and uptake when conjugated with 0:1 
aVCAM1:aE-selectin after both 1 h and 4 h incubations and when conjugated with 1:1 
aVCAM1:aE-selectin after 1 h incubation.  These results may indicate antibody 
diffusivity, as a result of membrane fluidity, has no effect on binding and uptake.   
However, the liposomal surfaces were completely saturated with antibodies.  In order to 
more accurately probe the question of antibody diffusivity we had to test our hypothesis  
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at very low antibody surface densities that would allow for greater lateral mobility.  It is 
also important to note from these studies that DSPC liposomes had significantly higher 
levels of non-specific binding and uptake than DOPC liposomes.  This overall increase 
in binding and uptake by non-activated ECs is evident at both the 4 h and 1 h incubation 
times.  Furthermore, non-specific IgG1-bearing and bare DSPC liposomes had 
significantly greater binding and uptake by activated ECs.  Although DSPC liposomes 
conjugated with high surface density of aE-selectin achieved high levels of binding and 
uptake, higher levels of binding to non-activated ECs present a problem for targeted 
drug delivery in  vivo, are non-desirable, and suggest there is an additional in  vitro 
binding and uptake mechanism other than the one initiated by E-selectin.    
  To further investigate our question regarding the effect of antibody diffusivity, we 
assessed binding and uptake as a function of antibody surface density and membrane 
fluidity.  We hypothesized that if the lateral antibody mobility would play a role on 
binding, then even at very small liposomal surface concentrations, binding and uptake 
levels similar to those observed with fully antibody saturated liposomes would take 
place only with unsaturated liposomes.  Using the antibody characterization technique 
of lipid coated glass microbeads presented in Chapter 2, we identified a specific regime 
in which a very limited number of antibody molecules would be bound on the liposomal 
surface.  We concluded this regime to be ranging from 1% to 7.5% of the total antibody 
concentration used previously to saturate the liposomal surface.  We determined these 
concentrations corresponded to a range of 7 ± 1 to 20 ± 3 aE-selectin molecules per 
DOPC liposome and between 5 ± 1 to 16 ± 6 aE-selectin molecules per DSPC 
liposomes.  Notably, DOPC liposomes conjugated with 2.5% and 7.5% of aE-selectin  
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had significant binding and uptake by activated ECs while DSPC liposomes did not.  
Efficient targeting of DOPC liposomes at low antibody densities could be potentially 
explained by two factors: increased antibody accumulation due to increased diffusivity 
or better exposure of the antibody’s binding sites due to a less crowded liposomal 
surface.  At 100% aE-selectin concentration, when the liposomal surfaces were 
saturated, both DOPC and DSPC liposomes localized on or within stimulated ECs more 
than likely due to an increased rate of antibody-E-selectin bond formation.  At low 
antibody densities, the non-specific binding and uptake of DSPC liposomes by non-
activated ECs was high again.  These results suggest again that DSPC liposomes may 
have a second binding and uptake mechanism in addition to targeted E-selectin binding 
and -mediated endocytosis.   
  We were interested in decoupling uptake and binding given that our previous 
experimental setup did not permit us to distinguish the fluorescence intensities of either 
one.  Our surface binding studies demonstrated DOPC had the highest binding at 1 h 
while DSPC had its binding peak at 0.5 h.  This rapid increase and decrease of DSPC 
binding remains unclear.  Our cellular internalizations studies, in turn, showed both 
DSPC and DOPC had maximal internalization after 1 h.  All non-specific binding control 
experiments showed no significant differences as expected.   
  Further studies are needed to continue investigating the role of antibody lateral 
mobility in liposome binding.  Liposomes with a different formulation that allows for low 
non-specific binding yet also has high membrane rigidity would be ideal to address this 
question.  The question of high levels of non-specific binding of saturated liposomes 
also requires further investigation.  Despite the multiple questions that arose in this aim,  
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we were able to demonstrate that the coupling of aE-selectin to either saturated or 
unsaturated liposomes led to high levels of binding and uptake in ECs.  DOPC 
liposomes with low antibody surface densities also had significant binding and uptake.  
This formulation could potentially continue to be explored for clinical drug delivery and 
targeting applications.  
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Chapter 4.  
In vivo Evaluation of PEGylated Liposome Biodistribution 
4.1 Introduction 
  Drug delivery systems that efficiently target inflamed vasculature can be 
beneficial for the detection and treatment of a wide range of diseases such as 
atherosclerosis.  As previously mentioned, a range of nanoparticle drug delivery 
systems, including liposomes, has been studied for these applications [118].   
Liposomes lacking any targeting moieties on their surfaces have been reported to 
efficiently deliver encapsulated dexamethasone to aortic plaques in an atherogenic 
mouse model [119].  Additionally, imaging agents targeting VCAM1 [10] and E-selectin 
[120] have been investigated for molecular imaging of unstable atherosclerotic plaque.  
Utilizing liposomes that target cell adhesion molecules and also carry imaging agents 
may lead to improved molecular imaging of unstable plaque.  Such work was, 
unfortunately, out of the scope of our present project.  In this study, we evaluated the in 
vitro uptake of DOPC PEGylated liposomes targeting E-selectin and assessed the 
biodistribution of these liposomes in mice.  We hypothesized the presence of PEG 
would increase liposome circulation time in the bloodstream.  We investigated how 
different surface densities and types of PEG functionalized lipids with varying polymer 
molecular weights had an effect on binding and uptake in ECs.  In vivo administration of 
PEGylated liposomes was traced in live mice via an in vivo imaging system.  Finally, 
liposome distribution was qualitatively examined by fluorescence imaging of tissue 
cryosections.    
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4.2 Materials and Methods 
4.2.1 Liposome Preparation 
Unilamellar liposomes were prepared by the extrusion method as previously 
described [13].  Two different types of functionalized polyethylene glycol (PEG) lipids 
were used for the in vitro and in vivo experiments in this aim: 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG),  1,2-di-(9Z-
octadecenoyl)-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-
5000], (DOPE-PEG) (Avanti Polar Lipids, Alabaster, AL). Mixtures of 99:1 DOPC:DSPE-
PEG, along with 94:5:1 and 90:5:5 DOPC:N-dod-PE:DOPE-PEG in chloroform were 
dried under a nitrogen stream. The lipids were then dissolved in a mixture of 
DMSO:EtOH (7:3 v/v). Lipid mixtures (1 ml) were injected in 6 ml 10 mM TES (Sigma 
Aldrich, St. Louis, MO) buffer (pH 7.4) with or without rhodamine-conjugated dextran (1 
mg/mL) while being agitated at 1000 rpm with a stir bar to yield 8.33 mM lipid. The 
multilamellar vesicles were subjected to 10 freeze-thaw cycles (utilizing liquid nitrogen) 
prior to extrusion. Large unilamellar vesicles were prepared by utilizing a LIPEX
TM 
extruder (Northern Lipids, Burnaby, BC, Canada). Vesicles were extruded 10 times 
through two 100 nm polycarbonate membranes (Whatman Nucleopore 25 mm track-
etched membranes, GE Healthcare Biosciences, Piscataway, NJ). Dextran-
encapsulated liposomes were dialyzed against 10 mM TES buffer using a Slide-A-Lyzer 
dialysis cassette (MWCO 20 kDa, Pierce Biotechnology, Inc., Rockford, IL) overnight at 
room temperature (RT). Liposome size was measured by dynamic light scattering on a 
ZetaPALS analyzer (Brookhaven Instruments, Corp., Holtsville, NY) in 10 mM TES 
buffer (pH 7.4).  The exact same procedure was repeated when preparing liposomes  
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tagged with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine perchlorate (DiD) 
(Life Technologies/Thermo Fisher Scientific, Grand Island, NY) for the in  vivo 
experiments. The same lipid formulations were used except 0.1 mol % DiD was added 
to the mixtures prior to drying with nitrogen gas.  DiD was kept sterile; all aliquots used 
for liposome preparation were prepared under sterile conditions.   
The concentration of lipid in solution was determined by a phosphate assay as 
previously described [13]. Briefly, a diluted liposome sample was ashed with 0.2 ml 
sulfuric acid (10% v/v) at 200°C for 1 h, followed by addition of 50 µl hydrogen peroxide 
(30% v/v) and further heating at 200°C for 40 min. After the sample was cooled down to 
room temperature, 480 ml deionized water and 0.5 ml of color reagent (0.5% w/v 
ammonium molybdate, 2% w/v ascorbic acid) were added to each sample followed by 
heating at 45°C for 20 min. The samples were read at 820 nm using a Spectramax Plus 
384 spectrophotometer (Molecular Devices, Sunnyvale, CA). A calibration curve was 
prepared with known phosphate quantities.  
4.2.2 Liposome-Antibody Conjugation  
  Antibodies were conjugated to liposomes via the N-dod-PE anchor. EDC (3 mg) 
and NHS (4 mg) (Sigma Aldrich, St. Louis, MO) were added to 8.33 mM lipid 
(liposomes) in 10 mM TES buffer (pH 7.4) and incubated for 6 h at room temperature.  
Excess EDC and NHS were removed using Slide-a-Lyzer dialysis cassettes (20 kDa 
MWCO). IgG1 isotype monoclonal antibody (mAb) (100 mol%, non-specific binding 
control) or aE-selectin mAbs were added to EDC-modified liposomes at a molar ratio of 
1:1000 antibody:phospholipids and incubated overnight at room temperature.  All mAbs  
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were purchased from R&D Systems (Minneapolis, MN). Free antibodies were separated 
using Float-a-Lyzer dialysis tubes (300 kDa, Spectrum Labs, Rancho Dominguez, CA) 
dialyzed against 10 mM TES buffer at pH 7.4.   
4.2.3 Cell Culture 
Human umbilical vein endothelial cells (ECs) were grown in endothelial growth 
medium-2 (EGM-2) with supplements as described by the distributor (Lonza, Allendale, 
NJ). Cells were maintained at 37°C in a humidified incubator with 5% CO2 and used for 
experiments always at passage 4. Growth medium was changed the day after cell 
seeding and every other day thereafter.  
4.2.4 Liposome Uptake by ECs 
Liposome binding and uptake was first assessed by incubating ECs with 
liposomes encapsulating rhodamine-dextran.  Liposome binding and uptake by ECs 
was analyzed using flow cytometry as previously described [21, 22].  ECs were seeded 
in 6-well plates (3 x 10
5 cells/well) and allowed to adhere overnight.  After activation with 
IL-1 (5 ng/ml) for 6 h, ECs were incubated for 1 h at 37°C with PEGylated dextran-
loaded: (1) nonspecific (IgG1) liposomes; (2) bare liposomes (no antibodies conjugated 
on liposome surface); and (3) liposomes conjugated with aE-selectin mAbs.  The dose 
or liposome concentration used with ECs was 1 μmol lipid/10
6 cells. 
Treated ECs were washed with PBS, harvested using a 0.25% trypsin solution, 
and collected in a polystyrene culture tube. Cells were further washed with ice cold PBS 
three times.  Binding and uptake data were acquired using an LSRII flow cytometry 
analyzer (BD Immunocytometry Systems, San Jose, CA) and analyzed with WEASEL  
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software developed by WEHI (Parkville, Australia).  A total of 30,000 events per sample 
were analyzed to generate each histogram.  Again we chose to present data in its raw 
format instead of a normalized version.  Significant differences in liposome uptake were 
evaluated using a 2-way ANOVA statistical analysis.  A p value less than 0.05 was 
considered statistically significant.  
4.2.5 In Vivo Studies  
All animal work was approved by Harvard University’s Institutional Animal Care 
and Use Committee (IACUC). C57BL/6J female mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME) and were between 7-8 weeks of age at the time of 
experiments.  Four mice were given tail vein injections of 0.1 ml DiD-labeled liposomes. 
The detailed conditions are as follows: mouse #1 - bare liposomes containing 5% 
DOPE-PEG, mouse #2 – liposomes conjugated with aE-selectin mAbs, mice #3 and #4 
– liposomes containing 5% DOPE-PEG and conjugated with aE-selectin mAbs.  One of 
the mice, mouse #4, was injected with PEGylated liposomes conjugated with aE-
selectin was also injected intravenously with 0.3 µg of IL-1α dissolved in 0.2 ml sterile 
1X PBS.  The cytokine injection was given 30 min prior to injecting liposomes.  All four 
mice were imaged using the in  vivo  imaging Xenogen IVIS Spectrum (Caliper Life 
Sciences/Perkin Elmer, Hopkinton, MA) system to track the accumulation of fluorescent 
liposomes.  The images were normalized by subtracting background signal prior to 
initializing the in  vivo imaging procedure.  Radiance measurements had units of 
photons/sec/cm
2/sr, which refers to the number of photons per second that are leaving 
a square centimeter of tissue and radiating into a solid angle of one steradian (sr).  The 
fluorescence signals were quantified by an efficiency measurement where the emission  
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image is normalized (divided) by a stored reference image of the excitation light 
intensity and has arbitrary units (A.U.).  This efficiency measurement was calculated by 
Living Image Software (Caliper Life Sciences/Perkin Elmer, Hopkinton, MA).  Images 
were taken at 1 min, 1 h, 2h, 11h, and 12 h after intravenous liposome injections.  Mice 
injected with bare, PEGylated and non-PEGylated, aE-selectin-conjugated liposomes 
were euthanized 1 h after liposome injection.  Mice injected with PEGylated, aE-
selectin-conjugated liposomes were imaged 1 h post-injection and euthanized 12 h 
post-injection.   
4.2.6 Tissue Harvest 
  The following organs were immediately excised after euthanasia: liver, spleen, 
kidneys, heart, abdominal aorta, and lungs.  The organs were imaged immediately after 
excision using the Xenogen IVIS Spectrum system.  Once imaged, the organs were 
placed in a 30% sucrose solution within minutes and stored at 4 °C for a maximum of 
one day until the tissue samples were processed for morphologic analysis.  Tissue 
samples were embedded in Tissue-Tek® O.C.T. Compound (VWR, Radnor, PA) and 
frozen at -80 °C.  Frozen samples were cryosectioned at a 6 µm thickness using a Leica 
cryostat (Leica Biosystems, Buffalo Grove, IL) and tissue sections were placed on 
SuperFrost Plus glass slides (VWR, Radnor, PA).  All samples were stored at -80 °C.   
4.2.7 Fluorescence Imaging of Tissue Samples 
  Tissue sections were imaged using a Zeiss Axio Observer Z1 inverted 
fluorescence microscope (Carl Zeiss, Thornwood, NY) equipped with a Hammamatsu 
Orca-Flash camera using the DAPI and Cy5 filter cubes as well brightfield and phase  
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contrast modes.  Images were taken using the 10X, 20X, and 40X objectives.  Tissue 
sections were mounted with VECTASHIELD® mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA) and sealed prior to imaging.  
 
4.3 Results  
4.3.1 In Vitro Evaluation of PEGylated Liposomes  
  It is now widely known the addition of a small fraction of PEG to liposome 
formulations dramatically increases the distribution half-life [121,122].  This has been 
demonstrated in pre-clinical studies [123,124] and in clinical studies [125].  Thus, we 
hypothesized incorporation of the polymer molecule would achieve similar blood 
circulation times in our in  vivo studies.  We investigated the binding and uptake of 
liposomes having the same basic formulation of unsaturated DOPC tested in the 
previous two aims, but this time we incorporated various amounts of DSPE-PEG and 
DOPE-PEG in their formulation.   
  First, we assessed the binding and uptake of liposomes that included 1 mol % of 
DSPE-PEG with a molecular weight of 2000 Da.  Each lipid molecule was functionalized 
with one terminal amine group, as shown on Figure 4.1 (A), which served as a 
conjugation anchor for antibodies in substitution for N-dod-PE’s terminal carboxyl group 
used previously.  Liposomes conjugated with aE-selectin showed again a significant 
different in binding and uptake by activated ECs compared to controls (Figure 4.1 (B)).  
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  Figure 4.1: Flow cytometry evaluation of amine functionalized-PEGylated 
liposome binding and uptake by ECs after 1 h incubation.  DSPE-PEG had a 
molecular weight of 2000 Da and was functionalized with a terminal amine group (A).  
Non-activated and activated ECs (IL-1α, 6 h) were treated with DOPC:DSPE-PEG (99:1 
mol:mol) liposomes encapsulating rhodamine-labeled dextran and without antibody 
surface conjugation (bare) or conjugated with either IgG1 or aE-selectin mAbs for 1 h 
(B).  Results shown are raw mean fluorescence intensity (MFI) values.  Error bars are 
reported as standard deviation, n = 3.  Statistical significance was calculated using a 
two-way ANOVA test (*p < 0.05, **p < 0.01, and ***p < 0.001). 
A 
B  
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  We simultaneously tested two other lipid formulations with unsaturated DOPE-
PEG (Figure 4.1 (A)), which had a molecular weight of 5000 Da. 1 and 5 mol % of 
DOPE-PEG were incorporated into the formulation along with 5 mol % of N-dod-PE, 
which served as the antibody conjugation anchor.  Both formulations had increased 
binding and uptake by activated ECs when aE-selectin mAbs were conjugated on the 
surface (Figure 4.1 (B) and  (C)).  However, DOPC liposomes containing 1 mol % 
DOPE-PEG had high non-specific binding and uptake by both bare and IgG1 conjugated 
liposomes regardless of whether or not ECs were exposed to the cytokine.  DOPC 
liposomes containing 5 mol % DOPE-PEG, on the other hand, had lower non-specific 
binding, but achieved similar results when conjugated with aE-selectin mAbs.   
Differences in binding and uptake for this condition were statistically significant.   
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Figure 4.2: Flow cytometry evaluation of PEGylated liposome binding and uptake 
by ECs after 1 h incubation.  DOPE-PEG (A) had a molecular weight of 5000 Da.  
Non-activated and activated ECs (IL-1α, 6 h) were treated with DOPC:N-dod-PE:DOPE- 
B 
C 
A  
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Figure 4.2 (Continued): PEG (94:5:1 mol:mol:mol) (B) and DOPC:N-dod-PE:DOPE-
PEG (90:5:5 mol:mol:mol) (C) liposomes encapsulating rhodamine-labeled dextran and 
without antibody surface conjugation (bare) or conjugated with either IgG1 or aE-selectin 
mAbs for 1 h.  Results shown are raw mean fluorescence intensity (MFI) values.  Error 
bars are reported as standard deviation, n = 3.  Statistical significance was calculated 
using a two-way ANOVA test (*p < 0.05, **p < 0.01, and ***p < 0.001). 
 
4.3.2 In Vivo Evaluation of Biodistribution of DOPC PEGylated Liposomes  
Based on the previously mentioned in vitro results, we decided to use DOPC:N-
dod-PE:DOPE-PEG (90:5:5 mol:mol:mol) liposomes conjugated with aE-selectin for our 
small in vivo pilot study.  An additional 0.5 mol % of DiD was added to the formulation in 
order to adequately label liposomes to be detected by the in vivo imaging system (IVIS).  
DiD is a lipophilic dialkylcarbocyanine dye which has been reported to have improved 
fluorescence yield and life-times when used in small rodents for in vivo imaging 
[126,127].  A total of four mice were used in this study.  Figures 4.3 and 4.4 
demonstrate the rapid accumulation of liposomes (within 1 h) in the liver and spleen.  
Qualitatively speaking, the accumulation of PEGylated, bare liposomes seemed to be 
more evident in the spleen than in the liver; while accumulation of PEGylated, aE-
selectin conjugated liposomes seemed to be high in both of these organs.   
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Figure 4.3:  In  vivo fluorescence imaging of mice injected with DiD labeled 
liposomes at 1 min post-injection.  Mice received a tail vein injection of liposomes 
containing 5% PEG and 0.5% DiD with aE-selectin conjugated on the surface (left) and 
without any antibody conjugated (right).  Image was captured after 1 min post-injection 
with a Xenogen IVIS Spectrum system to track the accumulation of fluorescent labeled 
liposomes. 
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Figure 4.4:  In  vivo fluorescence imaging of mice injected with DiD labeled 
liposomes at 61 min post-injection.  Mice received a tail vein injection of liposomes 
containing 5% PEG and 0.5% DiD with aE-selectin conjugated on the surface (left) and 
without any antibody conjugated (right).  Image was captured after 61 min post-injection 
with a Xenogen IVIS Spectrum system to track the accumulation of fluorescent labeled 
liposomes.  Arrows indicate increased accumulation of liposomes in the liver and 
spleen. 
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  After 1 h, the mouse which had been injected a dose of PEGylated, bare 
liposomes was euthanized and its organs excised and imaged via Xenogen IVIS 
Spectrum system as can be seen in Figure 4.5. The fluorescence signal was quantified 
by the radiant efficiency measurement.  The liver and spleens emitted the highest 
amount of fluorescent signals compared to all other organs.  The radiant efficiency of 
these organs was approximately 4.0 x 10
9 A.U.   
 
Figure 4.5:  In  vivo fluorescence imaging of excised mouse organs; bare 
liposome condition.  Mouse received a tail vein injection of bare liposomes containing 
1 
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3 
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89 
 
Figure 4.5 (Continued): 5% PEG and 0.5% DiD and was sacrificed after 1 h.  Liver (1), 
spleen (2), kidneys (3), heart (4), aorta (5), and lungs (6) were excised at this time.  
Image was captured immediately after organ excision with a Xenogen IVIS Spectrum 
system to track the accumulation of fluorescent labeled liposomes. 
  
  The mouse exposed to PEGylated, aE-selectin conjugated liposomes was kept 
alive for a total of 12 h.  A third mouse, placed on the center as shown in Figures 4.6 
and  4.7, was injected with 0.3 µg of IL-1α and then injected intravenously with 
PEGylated, aE-selectin conjugated liposomes.  Immediately after, a fourth mouse, 
placed on the right as shown in Figures 4.6 and 4.7, was injected intravenously with 
only non-PEGylated, aE-selectin conjugated liposomes.  After 1 min, no significant 
changes in fluorescent signal were apparent in the mouse exposed to the cytokine.  At 
this same time point, the mouse injected with non-PEGylated, aE-selectin conjugated 
liposomes on the right appeared to have rapid liposome localization to possibly the 
lungs, liver, and spleen, as the entire upper section of the body had a high fluorescent 
signal.  This same trend continued after 1 h (Figure 4.7) and there appeared to be no 
significant changes in the organ accumulation patterns of either three conditions. 
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Figure 4.6:  In  vivo fluorescence imaging of mice injected with DiD labeled 
liposomes at 61 and 1 min post-injection.  Mice received a tail vein injection of DiD 
labeled PEGylated liposomes with aE-selectin conjugated on the surface (center) and 
non-PEGylated liposomes (right).  Only mouse on the center received 0.3 µg IL-1α 
intravenously prior to liposome injection.  Mouse on the left was kept alive and is the 
same mouse from Figures 4.3 and 4.4.  Image was captured after 61 min post-injection 
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Figure 4.6 (Continued): for mouse on the left and after 1 min post-injection for mice on 
the center and right with a Xenogen IVIS Spectrum system to track the accumulation of 
fluorescent labeled liposomes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7:  In  vivo fluorescence imaging of mice injected with DiD labeled 
liposomes at 121 and 61 min post-injection.  Mice received a tail vein injection of DiD 
labeled PEGylated liposomes with aE-selectin conjugated on the surface (center) and 
non-PEGylated liposomes (right).  Only mouse on the center received 0.3 µg IL-1α 
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Figure 4.7 (Continued): intravenously prior to liposome injection.  Mouse on the left 
was kept alive and is the same mouse from Figures 4.3 and 4.4.  Image was captured 
after 121 min post-injection for mouse on the left and after 61 min post-injection for mice 
on the center and right with a Xenogen IVIS Spectrum system to track the accumulation 
of fluorescent labeled liposomes. 
 
  The mouse exposed to non-PEGylated, aE-selectin conjugated liposomes was 
euthanized 1 h after the liposome intravenous injection was administered to it.  Its 
organs were excised and imaged as shown in Figure 4.8.  High fluorescent signal was 
detected in the liver and spleen.  Radiant efficiency values were approximated between 
6 x 10
9 A.U. and 8 x 10
9 A.U.; the liver displayed the highest levels of fluorescence.   
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Figure 4.8:  In  vivo fluorescence imaging of excised mouse organs; non-
PEGylated, aE-selectin decorated liposome condition.  Mouse received a tail vein 
injection of non-PEGylated liposomes containing 0.5% DiD and aE-selectin on the 
surface.  Liver (1), spleen (2), kidneys (3), heart (4), aorta (5), and lungs (6) were 
excised immediately after sacrificing the mouse at 1 h post-injection time.  Image was 
captured promptly after organ excision with a Xenogen IVIS Spectrum system to track 
the accumulation of fluorescent labeled liposomes. 
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  Both mice injected with PEGylated liposomes conjugated with aE-selectin were 
monitored for a total of 12 h.  The image represented below (Figure 4.9) was taken at 
11 h post-liposome injection time and 11.5 h after the cytokine injection for the mouse 
on the right.  Although the large and small intestines have emitted some fluorescence 
signal, the highest liposome accumulation appeared to be in the spleen for both 
animals.  At this time, 12 h had passed since the mouse on the left, which was not 
exposed to IL-1α, received the liposome injection and thus, it was euthanized.  The last 
mouse (Figure 4.9 (right)) was euthanized 1 h thereafter.   
Figure 4.9:  In vivo fluorescence imaging of mice injected with DiD labeled   
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Figure 4.9 (Continued): liposomes at 12 h and 11 h post-injection.  Mice received a 
tail vein injection of DiD labeled PEGylated liposomes with aE-selectin conjugated on 
the surface.  Only mouse on the right received 0.3 µg IL-1α intravenously prior to 
liposome injection.  Image was captured after 12 h and 11 h post-injection for mice on 
the left and right, respectively, with a Xenogen IVIS Spectrum system to track the 
accumulation of fluorescent labeled liposomes. 
 
  Organs of both animals were excised immediately after euthanasia and imaged 
using the IVIS system again.  Images are shown in Figures 4.10 and 4.11.  The mouse 
not exposed to cytokine IL-1α (Figure 4.10) shows a remarkable liposome accumulation 
in the spleen with an approximate radiant efficiency value of 3 x 10
9 A.U.  The liver and 
heart also display a high level of liposome accumulation, with radiant efficiency values 
of approximately 1.5 x 10
9 to 2 x 10
9 A.U.  Liposome accumulation of mouse exposed to 
IL-1α was fairly similar (Figure 4.11); the liver and spleen emitting the highest 
fluorescence intensity, which also oscillated from 1.5 x 10
9 to 2 x 10
9 A.U.  The heart 
had a lower radiant efficiency consisting of approximately 1.0 x 10
9 A.U.  
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Figure 4.10:  In vivo fluorescence imaging of excised mouse organs; PEGylated, 
aE-selectin decorated liposome condition.  Mouse received a tail vein injection of 
PEGylated liposomes containing 0.5% DiD and aE-selectin on the surface.  Liver (1), 
spleen (2), kidneys (3), heart (4), aorta (5), and lungs (6) were excised immediately after 
sacrificing the mouse at 12 h post-injection time.  Image was captured promptly after 
organ excision with a Xenogen IVIS Spectrum system to track the accumulation of 
fluorescent labeled liposomes. 
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Figure 4.11:  In vivo fluorescence imaging of excised mouse organs; IL-1α and 
PEGylated, aE-selectin decorated liposome condition.  Mouse received 0.3 µg IL-1α 
intravenously and then received a second tail vein injection of PEGylated liposomes 
containing 0.5% DiD and aE-selectin on the surface.  Liver (1), spleen (2), kidneys (3), 
heart (4), aorta (5), and lungs (6) were excised immediately after sacrificing the mouse 
at 12 h post-injection time.  Image was captured promptly after organ excision with a 
Xenogen IVIS Spectrum system to track the accumulation of fluorescent labeled 
liposomes. 
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4.3.3 Fluorescence Imaging of Liver and Aorta Tissue Sections  
Organs were preserved, processed, and cryosectioned into 6 µm thick sections. 
Liver tissue sections were stained with DAPI, mounted, and imaged under a 
fluorescence microscope.  Images confirmed mice euthanized 1 h post-injection of bare, 
PEGylated liposomes (Figure 4.12 (A)) and of non-PEGylated, aE-selectin conjugated 
liposomes (Figure 4.12 (B)) both had a high accumulation in the liver.  However, the 
distribution of the liposomes seemed to be different among different types of cells 
comprising the liver tissue.  Fluorescence of non-PEGylated liposomes was very 
punctate while bare, PEGylated liposomes’ fluorescence signal was uniformly 
distributed with round, small puncta of intense fluorescence.   
  Liver tissue sections of animals exposed to PEGylated liposomes conjugated 
with aE-selectin showed similar fluorescence overall (Figure 4.13).  Tissue sections 
from the animal exposed to IL-1α also displayed very round puncta of intense 
fluorescence.  On the other hand, these morphologic characteristics were not found in 
the cytokine-free condition, instead the general fluorescence pattern was similar to that 
of the non-PEGylated liposomes shown in Figure 4.12 (B). 
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Figure 4.12:  Fluorescence microscopy images of mouse liver tissue (bare vs. 
non-PEGylated liposomes).  Mice received a tail vein injection of bare liposomes 
containing 5% PEG (A) and non-PEGylated liposomes decorated with aE-selectin (B).  
Merged images are showing 6 µm thick cryostat sections of liver tissue with DAPI 
stained cell nuclei (in blue) and liposomes containing DiD (in red).  Scale bar, 20 µm. 
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Cross-sections of mouse aortas were cryosectioned and imaged.  Two primary, 
different morphological characteristics of the outline of the tunica intima, media, and 
adventitia were observed.   Sections of aortas from bare and aE-selectin conjugated, 
PEGylated liposome animal conditions had distinct folds (Figures 4.14 and 4.16) while 
the other two conditions displayed a normal oblong outline of the cross-sectioned blood 
vessel (Figures 4.15 and 4.17).  Low amounts of liposomes localized in all four tissue 
sections.  Bare, PEGylated liposomes displayed the most punctate fluorescence near 
the vicinity of the endothelium, most likely in the tunica media and adventitia (Figure 
4.14).  E-selectin conjugated liposomes appeared to have accumulated directly on the 
endothelial lining of the blood vessel and in tissue distal from the endothelium (Figures 
4.15 and 4.17).  High fluorescence signal was detected in the blood vessel lumen of the 
animal exposed to IL-1α (Figures 4.16). 
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Figure 4.14:  Microscopy images of mouse aortic tissue (bare liposomes).  Mice 
received a tail vein injection of bare liposomes containing 5% PEG and decorated with 
aE-selectin.  Images are showing 6 µm thick cryostat cross sectioned aortas under 
brightfield (A), DAPI fluorescence (B), DiD fluorescence (C), and the merged image with 
A 
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Figure 4.14 (Continued): DAPI stained cell nuclei (in blue) and liposomes containing 
DiD (in red) (D).  Scale bar, 40 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15:  Microscopy images of mouse aortic tissue (non-PEGylated 
liposomes).  Mice received a tail vein injection of liposomes decorated with aE-selectin.  
Images are showing 6 µm thick cryostat cross sectioned aortas under brightfield (A),  
A  B 
C D 
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Figure 4.15 (Continued): DAPI fluorescence (B), DiD fluorescence (C), and the 
merged image with DAPI stained cell nuclei (in blue) and liposomes containing DiD (in 
red) (D).  Scale bar, 40 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16:  Microscopy images of mouse aortic tissue (IL-1α, aE-selectin-
conjugated PEGylated liposomes).  Mice received a tail vein injection of 0.3 µg IL-1α 
C D 
B  A  
 
105 
 
Figure 4.16 (Continued): and a second injection of liposomes containing 5% PEG and 
decorated with aE-selectin.  Images are showing 6 µm thick cryostat cross sectioned 
aortas under brightfield (A), DAPI fluorescence (B), DiD fluorescence (C), and the 
merged image with DAPI stained cell nuclei (in blue) and liposomes containing DiD (in 
red) (D).  Scale bar, 40 µm. 
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Figure 4.17:  Microscopy images of mouse aortic tissue (aE-selectin-conjugated 
PEGylated liposomes).  Mice received a tail vein injection of liposomes containing 5% 
PEG and decorated with aE-selectin.  Images are showing 6 µm thick cryostat cross 
sectioned aortas under brightfield (A), DAPI fluorescence (B), DiD fluorescence (C), and 
the merged image with DAPI stained cell nuclei (in blue) and liposomes containing DiD 
(in red) (D).  Scale bar, 40 µm. 
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4.4 Discussion 
  The initial goal of this aim was to assess the targeting efficiency of aE-selectin 
conjugated liposomes to atherosclerotic lesions in an ApoE-/- knockout mouse model.  
Due to time constraints, we were only able to conduct a small pilot in vivo study to 
assess liposome distribution in internal organ.  Liposomes directly targeting inflamed 
vasculature may have potential useful applications in the imaging and treatment of 
inflammatory vascular diseases such as atherosclerosis.  Previous studies have 
examined the targeting of aE-selectin conjugated liposomes to inflamed endothelium in 
different mouse models such as delayed type hypersensitivity (DTH) or skin 
inflammation [128], allergic or irritant contact dermatitis [129], glomerulonephritis [130], 
and rheumatoid arthritis [131].  In our studies, we examined the effect of PEG and 
cytokine IL-1α on the biodistribution of liposomes. 
The use of PEG in liposome formulations to enhance blood plasma half-life is 
well documented [121–123,132].  We chose to compare the EC binding and uptake of 
rhodamine dextran loaded-liposomes bearing two different types of PEG molecules, 
amine functionalized DSPE-PEG(2000 Da) and DOPE-PEG(5000 Da), at three different 
concentrations.  All three formulations had significant increase in uptake when 
conjugated with aE-selectin.  Liposomes including 5 mol % of DOPE-PEG(5000 Da) 
had the lowest non-specific binding and was chosen to be tested in vivo.  It should be 
noted, however, that all three formulations had significantly decreased MFI values in 
vitro compared to DOPC non-PEGylated liposomes studies discussed in the previous 
aim.  Increasing the density of PEG moieties on nanoparticle surfaces has been shown 
to decrease uptake by non-parenchymal rat liver cells [133].  Further in vitro binding and  
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uptake characterization of our liposome system incorporating PEG is needed in order to 
optimize PEG type, concentration, and molecular weight to be used in our system.   
We evaluated the biodistribution of DiD labeled liposomes with different surface 
modifications via the in  vivo  imaging Xenogen IVIS Spectrum system.  Table 4.1 
summarizes the fluorescence radiant efficiencies of the organs with the highest 
accumulation of liposomes: liver, spleen, and heart.   
Table 4.1: Summary of IVIS Fluorescence Quantification in Excised Organs 
Condition  Fluorescence Radiant Efficiency (A.U.) 
  Liver Spleen  Heart 
Bare, 5% PEG  4 x 10
9  4 x 10
9  2 x 10
9 
aE-selectin  8 x 10
9  6 x 10
9  2 x 10
9 
IL-1α, aE-selectin, 5% PEG  1.5 x 10
9  1.5 x 10
9  1 x 10
9 
aE-selectin, 5% PEG  2 x 10
9  3 x 10
9  1.5 x 10
9 
 
Based on our results, we concluded PEG decreases the uptake of liposomes by 
the reticuloendothelial system (RES).  Non-PEGylated liposomes had the highest 
accumulation in the liver and spleen.  The overall low fluorescence values of organs 
excised from mice exposed to PEGylated, aE-selectin conjugated liposomes was 
possibly due to renal clearance by the mice since they were euthanized 12 h after the 
liposome injection was administered to them.  The hearts and aortas had low 
fluorescence values across conditions.  Injection of IL-1α did not seem to lead to 
vascular inflammation; however this was not assessed by immunocytochemistry or any  
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other means.  Previously, intraplantar injections of TNF-α have been reported to induce 
local inflammation of mouse paw edema [131].  Intravenous injections of IL-1α have 
also been reported to induce production of IL-6 [134].  In addition, expression of E-
selectin on mouse endothelial cells in the cremaster muscle venules was reported to 
have been induced via local injections of TNF-α.  No studies have previously reported 
on the use of intravenous IL-1α in mice to induce vascular inflammation.  Almost all 
studies addressing vascular inflammation targeting, in the context of atherosclerosis, 
have used the ApoE-/- knockout mouse model due to its capability to develop 
atherosclerotic lesions of all stages that closely resemble lesions found in humans 
[135].  Hence, more optimization of injection dose and timing along with complementary 
characterization of inflammation in the murine vasculature is required in order to confirm 
expression of cell adhesion molecules on EC surfaces as a result of intravenous 
delivery of IL-1α. 
Liver and aorta tissue sections were examined by fluorescence microscopy.   
Based on literature reporting on liver tissue histology, cells displaying large, round 
nuclei have been identified to be hepatocytes, while those displaying dense, oblong 
nuclei are known to be either Kupffer cells or stellate cells if Ito [136].  Due the similarity 
in shape between our liposome fluorescence signal and immunocytochemistry images 
of Kupffer cells, we speculated the punctate regions we observed could potentially be 
liposomes that have been internalized by this type of cell [137].  Additionally, punctate 
regions of fluorescence coincide in location with smaller oblong nuclei, which further 
supports the idea that liposomes were internalized by these cells, which are the 
macrophages of the liver and part of the RES.   
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The fluorescence signal detected in aorta tissue sections was relatively low 
across conditions, which correlates with the results reported in Table 4.1.  Variations in 
the morphology of aortic cross-sections could potentially be due to imperfections in the 
dissection of the four different vessels, which affected the placement of the vessels 
within the O.C.T. medium when processing the tissue.  In addition, the vessels were 
more than likely not sectioned exactly at the same location, although we attempted to 
cryosection roughly the same depth.  Intense fluorescence detected in the aortic lumen 
of the animal exposed to IL-1α.  The lack of organ perfusion with saline to remove all 
blood in our studies prior to euthanasia may have led to auto-fluorescence of red blood 
cells detected in the vessel lumen.   
In summary, we evaluated the biodistribution of liposomes including PEG and 
aE-selectin in their formulation.  Non-PEGylated liposomes accumulated rapidly, within 
an hour, in the liver and spleen due to rapid clearance by the RES, more than likely.  
We determined the inclusion of PEG in our liposomal compositions enhanced blood 
circulation times by decreasing hepatic and splenic uptake.  Further studies need to be 
done to optimize PEG concentration and an in vitro model of vascular inflammation via 
intravenous injection of IL-1α.  Alternatively, an ApoE-/- knockout mouse model could 
be utilized to assess differences in DOPC and DSPC targeting to plaque lesions.   
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Chapter 5.  
Future Directions and Dissertation Summary 
  In this section, we propose potential future experiments that may serve to 
address questions that stemmed from our work in the previous aims.    
 
5.1 Further In Vitro Experiments 
5.1.1 Optimization of New Liposome Formulation  
  To further probe the question of how antibody diffusivity affects binding and 
uptake of liposomes in ECs, we need to design a new liposomal formulation that can 
have low non-specific binding and uptake, in a level parallel to DOPC, but still retain a 
low membrane fluidity state.  We propose two directions to optimize our formulation.  
The first is to replace DSPC with another saturated lipid that would be in a gel phase at 
temperatures close to 37 °C such as 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine 
(Tm  = 50 °C), 1,2-dinonadecanoyl-sn-glycero-3-phosphocholine (Tm  = 62 °C), or 1,2-
diarachidoyl-sn-glycero-3-phosphocholine (Tm = 66 °C).  The second option is to keep 
DOPC as a main component of such new formulation but incrementally add cholesterol, 
which has been reported to rigidify membranes [138], and a saturated lipid as a third 
component.  The cell membrane is not a pure fluid phase membrane; it is a mosaic with 
liquid ordered and disordered domains that has been shown to have constrained lateral 
diffusion [139].  A molar ratio of 35:35:30 unsaturated lipid:saturated lipid:cholesterol 
has been shown to induce lateral phase separation of lipids and lead to the formation of  
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domains in giant unilamellar vesicles (GUVs) [140,141], which attempts to mimic this 
constrained lateral diffusion found naturally in cell membranes.  We have prepared 
GUVs with a ternary mixture composed of 1:1 DOPC:DSPC and 30% cholesterol and 
showed the formation of lipid domains (Figure 5.1).  We have also prepared GUVs 
incorporating N-dod-PE and have shown the existence of domains at physiologically 
relevant temperature (37 °C) (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Giant unilamellar vesicles (GUVs) show lipid phase separation.  GUVs 
were prepared via the hydration method using the following mixture of lipids: 1:1  
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Figure 5.2 (Continued): The formulation also included 0.1% DiI in order to 
fluorescently label the vesicles.  Fluorescence microscopy images (A) – (C) were taken 
at 37 °C and show the vesicle on different imaging planes.  Scale bar, 5 µm.   
 
If we prepare liposomes that contain lipid domains, lateral diffusion of membrane 
components is likely to be less than that of pure DOPC liposomes.  We can examine 
membrane fluidity in giant unilamellar vesicles (GUVs) using a Bodipy-cholesterol 
derivative as previously reported [142] to determine if these mixtures have decreased 
fluidity in comparison with 95:5 DOPC:N-dod-PE vesicles.  If there are significant 
differences in membrane fluidity, we can investigate binding and uptake with 100 nm 
liposomes, as done previously in Chapters 2 and 3, and determine if liposomes 
composed of these new formulations show reduced non-specific binding.   
5.1.2 Non-Specific Cell Binding of 95:5 DSPC:N-dod-PE Liposomes 
The question of what gives rise to DSPC’s high binding and uptake levels in non-
activated ECs across conditions and in non-specific bare and IgG1  conditions in 
activated ECs remains unanswered.  Non-activated EC binding by DSPC liposomes 
was observed to be dependent on aE-selectin surface densities when antibody 
concentrations were low (Figure 3.3).  Furthermore, binding and uptake was not 
dependent on the control IgG1 surface densities; high levels are observed across 
antibody concentrations.  These results suggest aE-selectin plays a role in driving the 
binding and uptake of DSPC liposomes in non-activated ECs.  However, at 100% aE-
selectin concentrations, non-activated ECs did not show increased binding and uptake  
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relative to bare liposomes in other experiments (Figures 3.1 and 3.2).  These results 
could suggest a different mechanism, in addition to aE-selectin, such as differences in 
the physical properties between DOPC and DSPC that could influence binding and 
uptake in non-activated ECs.  
Differences in liposomal membrane fluidity have been shown to have an effect on 
which opsonin molecules liposomes attract to their surface in the presence of serum 
[143].  Intracellular digestion of saturated liposomes occurs faster than of unsaturated 
liposomes and is also dependent on the lipid chain length [144].  Clearly, the physical 
properties of phospholipids have an effect on cells.  We can further explore this area by 
determining if non-specific binding is an isolated event that only occurs with DSPC 
liposomes or if other saturated liposomes respond in the same manner.  We can 
measure binding and uptake by flow cytometry, as we previously have, so that we are 
able to directly compare our results.  We also propose to do a membrane fusion assay 
in order to determine if this non-specific binding is caused by spontaneous fusion of 
liposome and cell membranes.  Membrane fusion experiments can be performed based 
on previous reports [145,146].  We can test the extent of membrane fusion, measured 
by lipid mixing, of liposomes incorporating saturated lipids at different concentrations 
with endothelial cells and target liposomes.    
5.1.3 Potential Domain Formation in 95:5 DSPC:N-dod-PE Liposomes 
  Due to the main differences observed in EC binding and uptake between 95:5 
DOPC:N-dod-PE and DSPC:N-dod-PE liposomes, the idea that segregation of N-dod-
PE liposomes into lipid rafts occurred on 95:5 DSPC:N-dod-PE liposomes warrants  
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further investigation.  Lipid rafts have been subject of increased attention; studies 
suggest lipid rafts bring proteins in close proximity to one another and activate cell 
signaling cascades [147].  Biological membranes are mostly composed of fluid, liquid 
disordered phase lipids, but also include gel phase lipids and cholesterol [148].  Lipid 
rafts or domains, both in cell and model membranes, are typically composed of 
saturated, liquid ordered lipids rich in cholesterol.   
In model membranes, formation of domains composed of both liquid ordered and 
liquid disordered lipids have been observed.  This suggests it is theoretically possible to 
observe fluid phase domains composed of N-dod-PE in our liposomes.  Control over 
domain lipid composition in model membranes has been achieved by varying the 
ternary lipid mixture composition of saturated lipids, unsaturated lipids, and cholesterol, 
as mentioned previously [141].  It has become clear, based on the vast majority of lipid 
domain studies (both theoretical and experimental) done in giant unilamellar vesicles 
(GUVs) or lipid bilayers, that the presence of a sterol molecule such as cholesterol, is 
necessary to induce lipid domain formation [140,141,149,150].  Our lipid mixtures did 
not include cholesterol, which suggests the formation of liquid ordered domains would 
be unlikely.  It is possible, however, that the coexistence of both liquid and gel phases 
could give rise to some aggregation of N-dod-PE molecules. 
  Feigenson et al. reported the coexistence of fluid and gel phases in GUVs 
composed of 80:20 saturated:unsaturated lipids observed by confocal fluorescence 
microscopy [151].  At this composition, fluid phase lipids did not form domains, but 
instead formed linear patterns.  This type of formation, also termed viscous fingering, 
observed at high saturated lipid compositions, has also been reported by Veatch et al.  
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[141].  Furthermore, when Feigenson et al. increased the saturated lipid composition to 
90%, no coexistence of fluid and gel phases was visually observed.  It is possible 
viscous fingering still occurred but was unable to be detected with the current optical 
resolution.  In this same study, the minimum size of domains was identified to be 300 
nm by 300 nm in GUVs of approximately 20 µm in diameter.  Based on these 
dimensions, the ratio of the surface area of one domain vs. the surface area of a GUV is 
calculated to be ~7%.  Our calculations suggest conjugated antibodies occupied 10% of 
the total surface area of our liposomes (d = 100 nm).  If we extrapolate this study’s 
results and assume that: 1) N-dod-PE aggregation occurred in our liposomes and 2) the 
surface area coverage of a GUV by a domain is the same in our liposomes; then this 
would imply most of the antibodies and therefore N-dod-PE molecules would be 
segregated into one single patch or domain.  This configuration may be possible, 
however the stability over time of this single domain formation is questionable, unless 
this configuration is energetically favorable.   
  It is important to take into account the timescales of domain formation in vesicles.  
The timescale of lipid molecule lateral exchange in membranes is in the order of  (10
-7 s) 
[151].  Current lipid domain detection methods such as fluorescence resonance energy 
transfer (FRET) cannot measure the characteristic lifetimes of nanoscopic domains due 
to the differences between the timescales of probe lifetimes (10
-9 s) and lipid molecule 
exchange.  In GUVs, macroscopic domains persist for at least 1 h at room temperature, 
but the timescale of nanoscopic domains is still unknown.   
  The formation of small aggregates of N-dod-PE molecules in our 95:5 DSPC:N-
dod-PE liposomes is theoretically possible.  However, the absence of cholesterol and  
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low unsaturated lipid content in our lipid mixtures, the formation of viscous fingering and 
not domains at high saturated lipid compositions, our liposome surface area constraints, 
and the rapid timescale of lipid molecule lateral exchange, suggest domain formation 
would be rather unlikely to occur.  A possible experiment to investigate domain 
formation can be to form SLBs with fluorescently labeled N-dod-PE molecules via 
carbodiimide chemistry.  Labeling can be done by forming a covalent bond between the 
terminal carboxyl group present in N-dod-PE and the primary amine group of lucifer 
yellow shown below in Figure 5.3.  
 
 
 
 
Figure 5.3: Chemical structure of fluorescent probe, lucifer yellow.   
 
Bilayers can be examined by confocal microscopy to check for the presence of 
domains.  In addition, A FRAP experiment including the following conditions can be 
conducted: 1) Rhodamine-DOPE labeled SLBs (100% DSPC), 2) lucifer yellow-labeled 
SLBs (95:5 DSPC:N-dod-PE), 3) 95:5 DSPC:N-dod-PE SLBs conjugated with FITC 
labeled aE-selectin.  We can then compare the diffusivities obtained with our previous 
results (rhodamine-DOPE labeled 95:5 DSPC:N-dod-PE SLBs); if domain formation  
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occurs, we would expect to detect a significant decrease in membrane diffusivity as 
reported by  Veatch et al. (~10
-2 µm
2/s) [152] relative to 100% DSPC bilayers.     
5.1.4 Low Binding and Uptake Levels of aVCAM1-Conjugated Liposomes 
  Liposomes, of both fluid and gel phase compositions, conjugated with 100% 
aVCAM1  showed binding and uptake levels comparable to that observed in non-
activated ECs (Figures 3.1 and 3.2).  Our previous report showed 2.8-fold increased 
binding of aVCAM1 conjugated liposomes by IL-1α activated ECs relative to IgG 
conjugated liposomes, however this was achieved at longer incubation times (12 h) 
[100].  It should be noted the same aVCAM1 monoclonal antibody, from the same 
vendor (R&D Systems) was utilized in these studies as well as in the studies presented 
in Chapter 3.  We measured VCAM1 expression to be approximately 10
4 molecules/cell 
(after 6 h activation with IL-1α), which is at or below the threshold required to observe 
enhanced binding [153].  Therefore, the low levels of binding and uptake observed 
could be potentially due to the low amount of VCAM1 surface expression in combination 
with the shorter liposome incubation time of 1 h. 
  Our low binding levels could also be due to low aVCAM1 functionality, which we 
did not test extensively.  We qualitatively assessed aVCAM1 functionality by 
immunocytochemistry of IL-1α activated ECs.  After activation, ECs were incubated with 
mouse anti-human aVCAM1 antibody (R&D Systems, Minneapolis, MN) and then 
stained with FITC-conjugated goat anti-mouse antibody as shown in Figure 2.4.  In 
order to quantitatively measure aVCAM1 functionality, we can perform a Western blot 
analysis of VCAM1 using EC lysates.  The same aVCAM1 antibody used consistently  
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throughout all of our liposome binding and uptake studies (catalog # BBA6) is also 
optimized to work in Western blot analyses.  aVCAM1 can be incubated with activated 
EC (IL-1α, 6 h) and non-activated EC lysate, in a serial dilution.  Incubation with buffer 
can be used as a control.  Binding can be quantified via chemiluminescence signal 
detection as reported previously [154].  A linear increase in signal with increased EC 
lysate concentration can quantitatively corroborate aVCAM1’s binding efficiency. 
Binding orientation of antibodies on nanoparticle surfaces is crucial for 
maximizing the functionality of the antibody and thus achieving optimal targeting.  Our 
conjugation method involved the covalent attachment of antibodies to N-dod-PE’s 
terminal carboxylic group via carbodiimide chemistry.  Unfortunately, this conjugation 
method does not control the antibody orientation at all, which could lead to low 
conjugation efficiencies and poor targeting.  To address the issue of the functionality of 
VCAM1 conjugated to liposomes, we can optimize antibody conjugation by further 
exploring other methods.  Recently, Kumar et al. reported a directional method of 
conjugation of antibodies to gold nanoparticles [155].  They achieved directionality by 
conjugating the Fc or non-targeting region of the antibody to the nanoparticles via a 
hydrazide-PEG-dithiol linker.  By using this linker, the Fab or targeting region of the 
antibody is exposed and directed away from the nanoparticle surface.  We can 
potentially adopt this method to our liposomal system by incorporating gold-labeled 
lipids into our liposomal compositions.  Dipalmitoyl phosphatidyl ethanolamine (DPPE) 
lipids conjugated with either 1.4 nm or 0.8 nm gold nanoparticles are commercially 
available (Nanoprobes, Yaphank, NY).   We can substitute N-dod-PE with gold-DPPE at 
various concentrations less than 5% (mol) and evaluate antibody surface densities and  
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binding efficiencies.  Additionally, the incorporation of gold-labeled lipids opens up a 
wide range of exciting imaging and diagnostic applications as well as therapeutic 
modalities such as temperature-controlled drug release.   
5.2 Theoretical Models of Nanoparticle Binding and Endocytosis 
  One of the first mathematical models describing the mechanics of receptor-
mediated endocytosis of nanoparticles was presented by Gao et al. in 2005.  In their 
model, they investigated the effect of nanoparticle size on receptor-mediated 
endocytosis.  The model assumes a spherical or cylindrical nanoparticle coated with 
immobile and evenly distributed ligands that is wrapped by a cell membrane containing 
mobile receptors.   The premise of the model is that upon initial binding of the 
nanoparticle ligands to the cell membrane surface receptors, cell membrane receptors 
are induced (by local receptor depletion) to diffuse and accumulate at the binding site 
and further form additional bonds.  An increase in the number of ligand-receptor bonds 
naturally gives rise to an increase in the binding energy.  In order for wrapping to occur, 
the binding energy must be greater than the cell membrane’s bending energy, κ, which 
is dependent upon the bending rigidity of the cell membrane, B, and is independent of 
nanoparticle size, as shown in the equation below. 
   8                                                                                                                           (5.1) 
The wrapping time and optimal nanoparticle size was calculated by keeping the 
following parameters constant: cell membrane bending rigidity (20 kBT), estimated 
receptor-ligand adhesion energy (15 kBT), diffusion of cell membrane receptors (10
4 
nm
2/s), number of cell membrane receptors (50 – 500/µm
2), and number of ligands  
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(5000/µm
2).  Gao et al. concluded that the optimal nanoparticle radius for maximal 
receptor-mediated endocytosis rate is in the order of 27 – 30 nm for spherical particles 
[111].   
  The effect of both nanoparticle size, shape, and ligand density on receptor-
mediated endocytosis has been previously investigated [156,157].  Endocytosis of 
nanoparticles has been shown to be size and shape dependent.  Furthermore, Yuan 
and Zhang showed that there exists an optimal range of nanoparticle size and ligand 
density at which the nanoparticle’s endocytotic time is minimized.  For example, for a 
nanoparticle with a radius of 30 nm, the optimal ligand density that gives rise to minimal 
wrapping time is calculated to be 1.  In contrast, for a nanoparticle with a radius of 50 
nm, similar to our liposome size, a ligand density of approximately 0.3 minimizes the 
endocytotic time.  Our estimated maximum ligand density in both 95:5 DOPC:N-dod-PE 
and DSPC:N-dod-PE liposomes was approximately 0.1.  These modeling results 
suggest that perhaps increasing our antibody densities from 0.1 to 0.3, by optimizing 
our antibody coupling method, can yield faster endocytotic uptake rates.   
  The bending rigidity of nanoparticles is often kept constant in mathematical 
models of endocytosis, yet it is a parameter that would obviously affect the process of 
nanoparticle wrapping by the cell membrane.  The lack of consideration for this 
parameter should be addressed because this parameter varies greatly depending on 
the material used to synthesize nanoparticles.  Polymer particles such as 
polybutadiene-polyethyleneoxide have a bending modulus in the order of 42 kBT [158], 
however other materials such as stiffer polymers, ceramics, and metals are much more 
rigid [159,160].  The liposomes investigated herein possess rigidities that are variable,  
 
123 
 
and further depend on the liposomal compositions.  For example, DOPC membranes 
have been shown to have a bending rigidity of 20 kBT [161,162] while a bending 
modulus in the order of 44 kBT has been measured in DSPC membranes [163].   
Recently, theoretical models have focused on the effect particle rigidity has on 
endocytotic uptake.  They have found that rigid particles are wrapped more easily by the 
cell membrane while softer particles are less prone to wrapping [164,165].  The 
adhesive interaction between a rigid particle and the cell membrane forces the 
membrane to deform upon binding.  On the other hand, softer particles initially spread 
along the cell membrane and do not deform the membrane until much later in the 
wrapping process.  This sudden rise in elastic energy at a later stage forces a larger 
adhesion energy to be present in order to achieve a balance and complete the 
endocytotic process.  95:5 DSPC:N-dod-PE liposomes functionalized with variety of 
ligand densities (including absence of ligands) had increased binding and uptake by 
cells displaying very low membrane receptor numbers, as well as at longer incubation 
times.  Based on these results, we can speculate that the 2-fold increase in DSPC 
liposomes’ bending modulus relative to DOPC may have played a role in the non-
specific uptake observed.  Our increased uptake of softer 95:5 DOPC:N-dod-PE 
liposomes by activated ECs can be explained under this model by assuming our softer 
vesicles had an increase in adhesion energy, enabled by 1:1 and 0:1 aVCAM1:aE-
selectin ligand densities, that is potentially able to overcome the elastic energy at the 
later stages of wrapping.  
  Mathematical models of the kinetics of antigen-antibody binding have been 
elucidated in the context of cell-cell adhesion [166] and biosensor experiments such as  
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surface plasmon resonance [167].  These models suggest forward reaction rates are 
expected to be dependent on the order of diffusion of receptors and ligands; both 
forward and reverse rates are reduced when either ligands or receptors are bound to a 
surface.  Nanoparticle size, shape, rigidity, cell membrane receptor diffusivity, and 
ligand densities have all been explored in theoretical models of receptor-mediated 
endocytosis.  To our knowledge, no theoretical models have focused on the effect of 
surface ligand diffusivity on nanoparticle endocytosis, to date.  Exploring the effects this 
parameter may have on nanoparticle uptake using theoretical models may be of great 
help in designing and optimizing liposomal parameters that may achieve enhanced 
endocytotic uptake rates. 
 
5.3 Further In Vivo Experiments  
  An ideal next step after optimizing in vitro targeting efficiency to ECs would be to 
ultimately test this efficiency in a small rodent model of inflammation.  If the application 
pursued is one for the development of therapeutic or diagnostic tool for atherosclerosis, 
then it would be best to perform studies in an apolipoprotein E-deficient (ApoE-/- 
knockout) mouse model.  This model is well established in the field and is known to 
develop atherosclerotic lesions in mice in a course of 8 to 14 weeks [135,168].    
We propose to continue to detect accumulation and targeting of liposomes to 
atherosclerotic plaque using the in vivo imaging system.  The design of ApoE-/- mice 
experiments can follow previously reported studies [169,170].  We can have two groups 
of mice, one would be fed an atherogenic diet and the control group would receive  
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normal chow.  At 12 weeks of age, mice can be administered a single dose of DiD 
labeled liposomes and we can image in vivo at t = 1 min, 1 h, 4 h, 12 h, and 24 h post-
injection.   Healthy and atherogenic mice can be further subdivided into 2 groups each, 
where one group would be euthanized after 1 h and the other after 24 h of liposome 
administration time.  This would allow us to determine if liposome binding occurs during 
the first hour and if accumulation increases at the lesion site with time.   
In order to assess the presence of cell adhesion molecules on the endothelium, 
quantify the extent of the atherosclerotic lesion, and further examine the distribution of 
liposomes, all organs should be dissected, fixed, and prepared for 
immunohistochemistry.  Euthanasia can be performed by administering mice with 100 
mg/kg of ketamine and 10 mg/kg of xylazine, as reported previously [169].  The mice 
should be perfused with PBS to eliminate traces of blood in the organs.  Tissue 
preservation can be done by perfusing 4% paraformaldehyde administered 
transcardially.  Tissues can be stained for CD31 or von Willebrand factor (vWf) to 
identify ECs as reported previously [171].  Oil Red O staining is a common histology 
method to quantify atherosclerosis development and can be used on aorta tissue 
sections [172].  Liposome accumulation in tissues can be measured by the IVIS 
Spectrum system immediately after dissection and by fluorescence microscopy on 
tissue sections.  Biodistribution can be assessed by examining spleen and liver tissue 
sections under fluorescence microscopy as well.   
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 5.4 Dissertation Summary  
  We first examined the temporal expression of cell adhesion molecules, VCAM1 
and E-selectin, on ECs stimulated with IL-1α and TNF-α, guided by previous gene 
expression results from our lab.  We determined an optimal concentration and exposure 
time to use in order to produce a high surface expression of VCAM1 and E-selectin on 
ECs in vitro.  These results were used to investigate liposome targeting to inflamed 
ECs.    
  We characterized the membrane fluidity of liposomes and supported lipid bilayers 
composed mostly of fluid phase, DOPC, and gel phase, DSPC.  We also quantified the 
antibody surface density of various ratios of antibodies conjugated to both DOPC and 
DSPC membranes.  Based on these results, we tested our hypothesis of how antibody 
diffusivity affected binding and uptake on ECs.  We decoupled liposome surface binding 
and internalization to further our understanding of liposomal fate once in contact with 
cells.  Finally, we carried out a preliminary in  vivo study where we looked at the 
biodistribution of liposomes conjugated with aE-selectin. 
  In general, this dissertation demonstrated that the presentation of only aE-
selectin was necessary to achieve enhanced targeting of activated ECs at short 
incubation times.  We determined that efficient targeting was also achieved at low 
antibody surface densities.  We cannot clearly discern if antibody diffusivity alone 
played a role on EC binding and uptake because DSPC may have a secondary binding 
and uptake mechanism.  However, we concluded that membrane fluidity influences EC 
binding and uptake, which should be further investigated.  Our work can be further  
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continued to set the foundation for efficient targeted drug delivery liposomal carriers that 
may have diagnostic and/or therapeutic potential for a broad range of inflammatory 
diseases including atherosclerosis.   
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Chapter 6.  
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6.2 Appendix B: Additional Statistical Analysis of Raw Flow Cytometry Data  
 
Table 6.1: Additional Statistical Analysis of 1 h Binding and Uptake by Non-Activated 
ECs Study.  Statistical significance was calculated using a two-way ANOVA test (ns = 
not significant, *p < 0.05, **p < 0.01, and ***p < 0.001). 
 IgG  vs. 
Bare 
IgG vs. 1:1 
aVCAM1:aE-
selectin 
IgG vs. 1:0 
aVCAM1:aE-
selectin 
IgG vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  ns  ns ns ns 
DSPC  * **  ns  * 
 
 
 
 
 
  Bare vs. 1:1 
aVCAM1:aE-
selectin 
Bare vs. 1:0 
aVCAM1:aE-
selectin 
Bare vs. 0:1 aVCAM1:aE-
selectin 
DOPC  ns ns ns 
DSPC  ns ns ns 
 1:1  aVCAM1:aE-
selectin vs. 1:0 
aVCAM1:aE-selectin 
1:1 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-selectin  
1:0 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-selectin 
DOPC  ns ns ns 
DSPC  ns ns ns  
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Table 6.2: Additional Statistical Analysis of 1 h Binding and Uptake by IL-1α-Activated 
ECs Study.  Statistical significance was calculated using a two-way ANOVA test (ns = 
not significant, *p < 0.05, **p < 0.01, and ***p < 0.001). 
  IgG vs. Bare  IgG vs. 1:1 
aVCAM1:aE-
selectin 
IgG vs. 1:0 
aVCAM1:aE-
selectin 
IgG vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  ns *** ns *** 
DSPC  ns *** ns *** 
 
  Bare vs. 1:1 
aVCAM1:aE-
selectin 
Bare vs. 1:0 
aVCAM1:aE-
selectin 
Bare vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  *** ns *** 
DSPC  *** ns *** 
 
 1:1  aVCAM1:aE-
selectin vs. 1:0 
aVCAM1:aE-selectin 
1:1 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-selectin 
1:0 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-selectin 
DOPC  *** *** *** 
DSPC  *** *** *** 
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Table 6.3: Additional statistical analysis of 4 h binding and uptake by non-activated ECs 
study.  Statistical significance was calculated using a two-way ANOVA test (ns = not 
significant, *p < 0.05, **p < 0.01, and ***p < 0.001). 
 IgG  vs. 
Bare 
IgG vs. 1:1 
aVCAM1:aE-
selectin 
IgG vs. 1:0 
aVCAM1:aE-
selectin 
IgG vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  ns  ns ns ns 
DSPC  ns  *** *** *** 
 
  Bare vs. 1:1 
aVCAM1:aE-selectin 
Bare vs. 1:0 
aVCAM1:aE-selectin 
Bare vs. 0:1 
aVCAM1:aE-selectin 
DOPC  ns ns ns 
DSPC  *** *** *** 
 
 1:1  aVCAM1:aE-
selectin vs. 1:0 
aVCAM1:aE-selectin 
1:1 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-selectin  
1:0 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-selectin 
DOPC  Ns ns ns 
DSPC  *** *** *** 
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Table 6.4: Additional Statistical Analysis of 4 h Binding and Uptake by IL-1α-Activated 
ECs Study.  Statistical significance was calculated using a two-way ANOVA test (ns = 
not significant, *p < 0.05, **p < 0.01, and ***p < 0.001). 
 
 IgG  vs. 
Bare 
IgG vs. 1:1 
aVCAM1:aE-
selectin 
IgG vs. 1:0 
aVCAM1:aE-
selectin 
IgG vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  ns ***  **  *** 
DSPC  ***  *** *** *** 
 
  Bare vs. 1:1 
aVCAM1:aE-
selectin 
Bare vs. 1:0 
aVCAM1:aE-
selectin 
Bare vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  *** ns *** 
DSPC  *** *** *** 
 
 
 1:1  aVCAM1:aE-
selectin vs. 1:0 
aVCAM1:aE-
selectin 
1:1 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-
selectin  
1:0 aVCAM1:aE-
selectin vs. 0:1 
aVCAM1:aE-
selectin 
DOPC  *** **  *** 
DSPC  *** **  *** 
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Table 6.5: Additional Statistical Analysis of Surface Binding Studies.  Statistical results of 
surface binding of IL-1α-activated ECs with mean fluorescence intensity values of NBD (A) and 
rhodamine (B).  Statistical significance was calculated using a two-way ANOVA test (ns = 
not significant, *p < 0.05, **p < 0.01, and ***p < 0.001). 
 
A 
  5 min vs. 0.5 h  5 min vs. 1 h  0.5 h vs. 1 h 
 
DOPC  ns ns  Ns 
DSPC  *** ns  *** 
 
 
B 
  5 min vs. 0.5 h  5 min vs. 1 h  0.5 h vs. 1 h 
 
DOPC  ns ***  *** 
DSPC  *** **  ** 
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Table 6.6: Additional Statistical Analysis of Cellular Internalization Studies.  Statistical 
results of cellular internalization of IL-1α-activated ECs with mean fluorescence intensity values 
of NBD (A) and rhodamine (B).  Statistical significance was calculated using a two-way 
ANOVA test (ns = not significant, *p < 0.05, **p < 0.01, and ***p < 0.001). 
 
A 
  5 min vs. 0.5 h  5 min vs. 1 h  0.5 h vs. 1 h 
 
DOPC  ns ***  ** 
DSPC  * ***  ** 
 
 
B 
  5 min vs. 0.5 h  5 min vs. 1 h  0.5 h vs. 1 h 
 
DOPC  ns   ***  *** 
DSPC  * ***  *** 
 
 
 